NZ618046B2 - Fc RECEPTOR BINDING PROTEINS - Google Patents
Fc RECEPTOR BINDING PROTEINS Download PDFInfo
- Publication number
- NZ618046B2 NZ618046B2 NZ618046A NZ61804612A NZ618046B2 NZ 618046 B2 NZ618046 B2 NZ 618046B2 NZ 618046 A NZ618046 A NZ 618046A NZ 61804612 A NZ61804612 A NZ 61804612A NZ 618046 B2 NZ618046 B2 NZ 618046B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- seq
- fcrn
- amino acid
- acid sequence
- Prior art date
Links
- 102000024070 binding proteins Human genes 0.000 title description 13
- 108091007650 binding proteins Proteins 0.000 title description 13
- 108010087819 Fc receptors Proteins 0.000 title description 5
- 102000009109 Fc receptors Human genes 0.000 title description 5
- 102000004965 antibodies Human genes 0.000 claims abstract description 429
- 108090001123 antibodies Proteins 0.000 claims abstract description 429
- 241000282414 Homo sapiens Species 0.000 claims abstract description 102
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 68
- 230000000694 effects Effects 0.000 claims abstract description 34
- 206010003816 Autoimmune disease Diseases 0.000 claims abstract description 27
- 230000000051 modifying Effects 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 102100014838 FCGRT Human genes 0.000 claims abstract 10
- 101710003435 FCGRT Proteins 0.000 claims abstract 10
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims description 47
- 108020004707 nucleic acids Proteins 0.000 claims description 40
- 230000036499 Half live Effects 0.000 claims description 16
- 230000003993 interaction Effects 0.000 claims description 16
- 230000000875 corresponding Effects 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 13
- 230000035693 Fab Effects 0.000 claims description 12
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 11
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 7
- 230000036947 Dissociation constant Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 4
- 108091006028 chimera Proteins 0.000 claims description 3
- 229940035295 Ting Drugs 0.000 claims description 2
- 230000027455 binding Effects 0.000 description 163
- 238000009739 binding Methods 0.000 description 155
- 210000004027 cells Anatomy 0.000 description 112
- 235000001014 amino acid Nutrition 0.000 description 71
- 101700027814 CDR3 Proteins 0.000 description 66
- 102000004851 Immunoglobulin G Human genes 0.000 description 64
- 108090001095 Immunoglobulin G Proteins 0.000 description 64
- 235000018102 proteins Nutrition 0.000 description 63
- 102000004169 proteins and genes Human genes 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 63
- 239000000203 mixture Substances 0.000 description 43
- 235000018417 cysteine Nutrition 0.000 description 41
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 39
- 210000004602 germ cell Anatomy 0.000 description 38
- 229920001184 polypeptide Polymers 0.000 description 38
- 102000018358 Immunoglobulins Human genes 0.000 description 34
- 108060003951 Immunoglobulins Proteins 0.000 description 34
- 201000010099 disease Diseases 0.000 description 30
- 238000006467 substitution reaction Methods 0.000 description 30
- 230000001225 therapeutic Effects 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 238000000034 method Methods 0.000 description 28
- 239000000427 antigen Substances 0.000 description 27
- 108091007172 antigens Proteins 0.000 description 26
- 102000038129 antigens Human genes 0.000 description 26
- 230000035492 administration Effects 0.000 description 25
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 23
- 239000000463 material Substances 0.000 description 22
- 238000004166 bioassay Methods 0.000 description 21
- 102000005614 monoclonal antibodies Human genes 0.000 description 21
- 108010045030 monoclonal antibodies Proteins 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 210000002381 Plasma Anatomy 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 210000004369 Blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- -1 cysteine amino acids Chemical class 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 13
- 206010025135 Lupus erythematosus Diseases 0.000 description 13
- 210000001519 tissues Anatomy 0.000 description 13
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 12
- 210000002966 Serum Anatomy 0.000 description 12
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 12
- 229960000060 monoclonal antibodies Drugs 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 210000000056 organs Anatomy 0.000 description 12
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 238000002703 mutagenesis Methods 0.000 description 11
- 231100000350 mutagenesis Toxicity 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 11
- 238000001542 size-exclusion chromatography Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000001809 detectable Effects 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000001965 increased Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 101710014346 CRNKL1 Proteins 0.000 description 7
- 102100003404 HLA-G Human genes 0.000 description 7
- 101710008996 HLA-G Proteins 0.000 description 7
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 7
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 7
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 7
- 241000282567 Macaca fascicularis Species 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000001404 mediated Effects 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000002823 phage display Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 150000003573 thiols Chemical class 0.000 description 7
- 210000003719 B-Lymphocytes Anatomy 0.000 description 6
- 210000003754 Fetus Anatomy 0.000 description 6
- 210000004408 Hybridomas Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 230000001580 bacterial Effects 0.000 description 6
- 230000001419 dependent Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000002919 epithelial cells Anatomy 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000002609 media Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 5
- 229960001230 Asparagine Drugs 0.000 description 5
- 229960000789 Guanidine Hydrochloride Drugs 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- 210000000987 Immune System Anatomy 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 230000037165 Serum Concentration Effects 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 210000001744 T-Lymphocytes Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- 102000027675 major histocompatibility complex family Human genes 0.000 description 5
- 108091007937 major histocompatibility complex family Proteins 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000002831 pharmacologic agent Substances 0.000 description 5
- 230000001105 regulatory Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- 108090000206 Autoantibodies Proteins 0.000 description 4
- 102000003852 Autoantibodies Human genes 0.000 description 4
- 210000001772 Blood Platelets Anatomy 0.000 description 4
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 4
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 4
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- SZVJSHCCFOBDDC-UHFFFAOYSA-N Iron(II,III) oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 210000004080 Milk Anatomy 0.000 description 4
- 241000721454 Pemphigus Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 4
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 4
- 210000003491 Skin Anatomy 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement Effects 0.000 description 4
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 4
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000003394 haemopoietic Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005291 magnetic Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 230000003278 mimic Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002285 radioactive Effects 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 231100000607 toxicokinetics Toxicity 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 3
- 101700027111 3SA0 Proteins 0.000 description 3
- 206010003246 Arthritis Diseases 0.000 description 3
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 102000011799 Desmoglein Human genes 0.000 description 3
- 108050002238 Desmoglein Proteins 0.000 description 3
- 210000001163 Endosomes Anatomy 0.000 description 3
- 230000036809 Fabs Effects 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 210000001503 Joints Anatomy 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 210000004379 Membranes Anatomy 0.000 description 3
- 108010035649 Natalizumab Proteins 0.000 description 3
- 229920000272 Oligonucleotide Polymers 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- 229960005190 Phenylalanine Drugs 0.000 description 3
- 206010036807 Progressive multifocal leukoencephalopathy Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000036462 Unbound Effects 0.000 description 3
- 210000003932 Urinary Bladder Anatomy 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000002519 immonomodulatory Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 200000000018 inflammatory disease Diseases 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229960005027 natalizumab Drugs 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 201000010874 syndrome Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 201000006704 ulcerative colitis Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- 208000007502 Anemia Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000000659 Autoimmune Lymphoproliferative Syndrome Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101710010587 CASP13 Proteins 0.000 description 2
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 230000037242 Cmax Effects 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 229920000453 Consensus sequence Polymers 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 101710007887 DHFR Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 210000002889 Endothelial Cells Anatomy 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010016256 Fatigue Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 101710008339 GOLPH3 Proteins 0.000 description 2
- 102100014497 GOLPH3 Human genes 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- 210000002216 Heart Anatomy 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 210000003712 Lysosomes Anatomy 0.000 description 2
- 102100000165 MS4A1 Human genes 0.000 description 2
- 101710010909 MS4A1 Proteins 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010028334 Muscle spasms Diseases 0.000 description 2
- 208000003795 Myasthenia Gravis, Autoimmune, Experimental Diseases 0.000 description 2
- 206010028549 Myeloid leukaemia Diseases 0.000 description 2
- 101700062818 NP Proteins 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 101710043203 P23p89 Proteins 0.000 description 2
- 206010057056 Paraneoplastic pemphigus Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 210000002826 Placenta Anatomy 0.000 description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
- 206010037844 Rash Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 210000002832 Shoulder Anatomy 0.000 description 2
- 206010040767 Sjogren's syndrome Diseases 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 239000002340 cardiotoxin Substances 0.000 description 2
- 231100000677 cardiotoxin Toxicity 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000003508 chemical denaturation Methods 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000005294 ferromagnetic Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 101710034616 gVIII-1 Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000003899 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001506 immunosuppresive Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002083 iodinating Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000001868 lysosomic Effects 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 101700045377 mvp1 Proteins 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005298 paramagnetic Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 201000011152 pemphigus Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002616 plasmapheresis Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 238000003498 protein array Methods 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 201000010208 seminoma Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000000392 somatic Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N 12-O-Tetradecanoylphorbol-13-acetate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZMKGDQSIRSGUDJ-IMVLJIQESA-N 33-[(E)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone Chemical compound CCCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-IMVLJIQESA-N 0.000 description 1
- PHEZJEYUWHETKO-UHFFFAOYSA-N 6-Fluoro-2-(2'-Fluoro-1,1'-Biphenyl-4-Yl)-3-Methylquinoline-4-Carboxylic Acid Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 101710043470 ATP5F1D Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 210000000628 Antibody-Producing Cells Anatomy 0.000 description 1
- 108090000298 Antinuclear Antibodies Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 230000036643 Apparent clearance Effects 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 210000000617 Arm Anatomy 0.000 description 1
- 206010003230 Arteritis Diseases 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000288575 Astomaea Species 0.000 description 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010065996 Autoimmune inner ear disease Diseases 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 101700071182 BPT1 Proteins 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010007539 Blocking Antibodies Proteins 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 208000004818 Bowen's Disease Diseases 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 229950010231 Brequinar Drugs 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 210000004900 C-terminal fragment Anatomy 0.000 description 1
- 101700033362 CD28 Proteins 0.000 description 1
- 102100019461 CD28 Human genes 0.000 description 1
- 102100013077 CD4 Human genes 0.000 description 1
- 101700022938 CD4 Proteins 0.000 description 1
- 101710040446 CD40 Proteins 0.000 description 1
- 102100013137 CD40 Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100003729 CD40LG Human genes 0.000 description 1
- 102100004444 CD58 Human genes 0.000 description 1
- 101710018147 CD58 Proteins 0.000 description 1
- 102100019453 CD7 Human genes 0.000 description 1
- 101700063101 CD7 Proteins 0.000 description 1
- 201000002829 CREST syndrome Diseases 0.000 description 1
- 102000000905 Cadherins Human genes 0.000 description 1
- 108050007957 Cadherins Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 102000004040 Capsid Proteins Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008072 Cerebellar syndrome Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 210000003467 Cheek Anatomy 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010008874 Chronic fatigue syndrome Diseases 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 1
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100010864 DSG1 Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010045579 Desmoglein 1 Proteins 0.000 description 1
- 102000007577 Desmoglein 3 Human genes 0.000 description 1
- 108010032035 Desmoglein 3 Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 230000035915 Distribution volume Effects 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000010118 Dystonia Diseases 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 229940073621 Enbrel Drugs 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 210000003038 Endothelium Anatomy 0.000 description 1
- 241000702371 Enterobacteria phage F1 Species 0.000 description 1
- 241000702374 Enterobacteria phage fd Species 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001492222 Epicoccum Species 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010016092 Faecal incontinence Diseases 0.000 description 1
- 206010062641 Female sexual arousal disease Diseases 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 210000001145 Finger Joint Anatomy 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 101710008404 GAPDH Proteins 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 208000009471 Gastroesophageal Reflux Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 210000004247 Hand Anatomy 0.000 description 1
- 208000003579 Hashimoto's encephalitis Diseases 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010019465 Hemiparesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000007475 Hemolytic Anemia Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 1
- 102100006815 IL2RA Human genes 0.000 description 1
- 101700082799 IL2RA Proteins 0.000 description 1
- 101700015336 ISG20 Proteins 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 206010022520 Intention tremor Diseases 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 210000003127 Knee Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 206010024190 Leiomyosarcomas Diseases 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010027183 Meniere's disease Diseases 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 210000004251 Milk, Human Anatomy 0.000 description 1
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 206010027925 Monoparesis Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 206010028632 Myokymia Diseases 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-Ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 208000004296 Neuralgia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000004235 Neutropenia Diseases 0.000 description 1
- 240000008962 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 206010029864 Nystagmus Diseases 0.000 description 1
- 206010063534 Ocular dysmetria Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010056662 Oligoclonal Bands Proteins 0.000 description 1
- 206010030875 Ophthalmoplegia Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 102100005499 PTPRC Human genes 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 210000001322 Periplasm Anatomy 0.000 description 1
- 206010034695 Pernicious anaemia Diseases 0.000 description 1
- 206010034701 Peroneal nerve palsy Diseases 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000004594 Persistent Fetal Circulation Syndrome Diseases 0.000 description 1
- 206010034962 Photopsia Diseases 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 102000020497 RNA-Binding Proteins Human genes 0.000 description 1
- 108091022184 RNA-Binding Proteins Proteins 0.000 description 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010038294 Reiter's syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005793 Restless Legs Syndrome Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000000395 SH3 domain Human genes 0.000 description 1
- 108050008861 SH3 domain Proteins 0.000 description 1
- 102100013834 SLC3A2 Human genes 0.000 description 1
- 101710007458 SLC3A2 Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010072148 Stiff person syndrome Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000002536 Stromal Cells Anatomy 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010043207 Temporal arteritis Diseases 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229940094937 Thioredoxin Drugs 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 210000003371 Toes Anatomy 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 206010044652 Trigeminal neuralgia Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940079023 Tysabri Drugs 0.000 description 1
- 206010046566 Urinary tract disease Diseases 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010052769 Vertigos Diseases 0.000 description 1
- 206010047385 Vestibular ataxia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 230000036835 Vz/F Effects 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- 210000003857 Wrist Joint Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 238000003016 alphascreen Methods 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000702 anti-platelet Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000005290 antiferromagnetic Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 101710003844 atpFH Proteins 0.000 description 1
- 101700015611 atpH Proteins 0.000 description 1
- 101710043468 atpP Proteins 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000035569 catabolism Effects 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 101700018328 ccdB Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000003196 chaotropic Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 101700067609 ctx Proteins 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 108010019249 cyclosporin G Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative Effects 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003210 demyelinating Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 201000003892 detrusor sphincter dyssynergia Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 108060000102 eco Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 108010010371 efalizumab Proteins 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002550 fecal Effects 0.000 description 1
- 201000008808 fibrosarcoma Diseases 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 201000005160 follicular thyroid carcinoma Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 201000006860 gastroesophageal reflux disease Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 108010023260 immunoglobulin Fv Proteins 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 201000001801 internuclear ophthalmoplegia Diseases 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910000529 magnetic ferrite Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 150000005002 naphthylamines Chemical class 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 230000002981 neuropathic Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000001151 non-parametric statistical test Methods 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N o-Nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910000065 phosphene Inorganic materials 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000272 proprioceptive Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000001179 pupillary Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000004805 robotic Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002412 selectin antagonist Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 201000002661 spondylitis Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 102000002933 thioredoxin family Human genes 0.000 description 1
- 108060008226 thioredoxin family Proteins 0.000 description 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100001072 toxicokinetic profile Toxicity 0.000 description 1
- 230000002110 toxicologic Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 239000000700 tracer Substances 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Abstract
Disclosed is an isolated antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the antibody binds to human FcRn; and wherein the VL comprises: (i) a VL CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14); (ii) a VL CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and (iii) a VL CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSIYV (SEQ ID NO: 13); and the VH comprises: (i) a VH CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22); (ii) a VH CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) a VH CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24). Further disclosed is the use of said antibody in the manufacture of a medicament for modulating an FcRn activity or for treating an autoimmune disorder. ng the amino acid sequence GDSQRPS (SEQ ID NO: 15); and (iii) a VL CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSIYV (SEQ ID NO: 13); and the VH comprises: (i) a VH CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22); (ii) a VH CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) a VH CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24). Further disclosed is the use of said antibody in the manufacture of a medicament for modulating an FcRn activity or for treating an autoimmune disorder.
Description
Fc RECEPTOR BINDING PROTEINS
RELATED ATIONS
This application claims priority under 35 U.S.C. §ll9 to United States ional
Application No. 6l/492,6l7, filed June 2, 2011, and Provisional Application No. 61/498,266,
filed June 17, 2011. The entire contents of both provisional applications are herein
incorporated by reference in their entirety.
FIELD OF THE INVENTION
The field of invention relates to ns that bind the Fc receptor.
BACKGROUND OF THE INVENTION
The most abundant antibody isotype in the serum is IgG and it has a critical role in
mediating protection against pathogens as well as in mediating allergic and inflammatory
responses that hasten recruitment of immune system components to the s, mucosae, and
dermal es (Junghans, Immunologic Research 29 (1997)). Moreover, it is also a
key component of a variety of autoimmune diseases. Under normal ions, the halflife of
IgG in the serum is in the range of 5—7 days in mice and 22—23 days in humans, which is a
prolonged , relative to the serum half life of other plasma proteins. In part, this occurs
because the neonatal FcRn receptor (FcRn) rescues pinocytosed IgG from degradative
lysosomes and es it back to the extracellular compartment (Junghans and Anderson,
Proc. Natl. Acad. Sci. USA 93:5512 (1996), Roopenian et al. J. Immunology 170:3528
(2003)).
FcRn binds to the the Fc portion of IgG. The interaction between the IgG Fc region
and FcRn is pH—dependent. Upon entry into cells by fluid phase endocytosis, IgG is
sequestered into endosomes and binds to FcRn with high affinity at acidic pH (6~6.5); when
the Rn complex cycles to the plasma membrane, IgG dissociates rapidly from FcRn in
the bloodstream at slightly basic pH (~7.4). By this receptor—mediated ing ism,
FcRn effectively rescues the IgG from degradation in lysosomes, thereby prolonging the half—
life of circulating IgG.
FcRn is a non—covalent heterodimer that typically resides in the endosomes of
endothelial and epithelial cells. It is a membrane bound receptor with a single—pass
transmembrane having three heavy chain alpha domains ((11, 0L2, and 0L3) and a single soluble
light chain B2—microglobulin (B2M) domain. Structurally, it belongs to a family of major
histocompatibility complex class 1 molecules that have B2M as a common light chain. The
FcRn or chain is a 46 kD protein composed of an ellular domain containing the (11, 0L2,
and 0L3 heavy chain domains, a transmembrane , and a relatively short cytoplasmic tail
(Burmeister et al. Nature 372:366 (1994)).
FcRn was first identified in the neonatal rat gut, where it functions to mediate the
absorption of IgG antibody from the mother’s milk and facilitates its transport to the
circulatory system (Leach et al. J Immunol 157:3317 (1996)). FcRn has also been isolated
from human placenta, where it also mediates absorption and transport of maternal IgG to the
fetal circulation. In adults, FcRn is expressed in a number of tissues, ing epithelial
tissues of the lung, instestine, , as well as nasal, vaginal, and biliary tress surfaces
(US. Patent Nos. 6,030,613 and 6,086,875; Israel et al. Immunology 92:69 (1997);
Kobayashi et al. Am J Physiol ; Renal Physiol 282:F358 (2002)).
In order to study the contributions of FcRn to IgG homeostasis, mice have been
engineered so that at least part of the genes encoding B2M and FcRn heavy chains have been
“knocked out” so that these proteins are not expressed (WO 02/43658; ns and
Anderson, Proc Natl Acad Sci US 93:5512 (1996)). In these mice, the serum ife and
concentrations of IgG were dramatically reduced, suggesting a FcRn dependent mechanism
for IgG homeostasis.
It has also been suggested that anti—human FcRn antibodies may be ted in these
FcRn knockout mice and that these dies may prevent the binding of IgG to FcRn.
However, such dies have not been generated or tested (WO 02/43658).
The inhibition of IgG binding to FcRn negatively alters IgG serum half—life by
preventing IgG recycling. This principle has been shown to be therapeutically effective in a
mouse model of autoimmune ous bullous diseases (Li et al. J Clin Invest 115:3440—
3450 (2005)). Accordingly, agents that block or antagonize the binding of IgG to FcRn may
be used in a method to treat or prevent autoimmune and inflammatory diseases or disorders
terized by the presence of inappropriately regulated IgG antibodies. An antagonistic
anti—rat FcRn monoclonal antibody (mAb)lG3 successfully prevented Experimental
Autoimmune Myasthenia Gravis (EAMG) in a rat passive model at a dose of 30 mg/kg; that
is about 100 fold lower than the intraveneous IgG (IVIG) used in treatment of MG, SLE, and
WO 67039
ITP. Further, FcRn—deficient mice genetically predisposed to develop autoimmune disorder
such as lupus or arthritis have icant reduction in severity of the disease.
SUMMARY OF THE INVENTION
The t disclosure provides isolated antibodies that bind the human Fc receptor,
nucleic acids encoding such antibodies, and methods of using these antibodies to detect
presence of FcRn, modulate Fc receptor activity, and treat autoimmune disorders.
Accordingly, one aspect of the t disclosure features an isolated antibody that
binds to human FcRn. This anti—FcRn antibody comprises a light chain variable region (VL)
that comprises a VL CDRl, a VL CDR2 and a VL CDR3 region, wherein the VL CDR3 region
has at least 85% (e. g., 90% or 95%) gy with the VL CDR3 region of SSYAGSGIYV
(SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13). Optionally, the VL CDRl and VL
CDR2 of the anti—FcRn antibody have at least 85% (e. g., at least 90% or 95%) gy
with the VL CDRl region TGTGSDVGSYNLVS (SEQ ID NO: 14) and VL CDR2 region
GDSQRPS (SEQ ID NO: 15), respectively. The anti—FcRn antibody does not have a cysteine
at the first position of at least one CDR3 region, e.g., at least one of the VL CDR3 regions.
In some embodiments, the above—described anti—FcRn antibody ses a VL CDRl
having at least 90% homology with VGSYNLVS (SEQ ID NO: 14), a VL CDR2
having at least 90% homology with GDSQRPS (SEQ ID , and/or a VL CDR3 having
at least 90% homology with SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID
NO: 13). In one example, the anti—FcRn antibody comprises the VL CDRl region
TGTGSDVGSYNLVS (SEQ ID NO: 14), the VL CDR2 region GDSQRPS (SEQ ID NO:15),
and/or the VL CDR3 region SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID
NO: 13).
In other embodiments, the isolated anti—FcRn antibody disclosed herein ses a
VL that comprises an amino acid sequence having at least 85% (e. g., at least 90%, 95% or
98%) homology with SEQ ID NO: 10 or SEQ ID NO:ll. In one example, the VL of the
isolated antibody comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO:ll.
Another aspect of the present sure features an isolated anti—FcRn antibody
comprising a light chain variable region (VL) that comprises a VL CDRl, a VL CDR2 and a
VL CDR3 region, wherein the VL CDR3 region has up to 3 amino acid substitutions as
compared to the following sequence: SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV
(SEQ ID NO: 13), and wherein the ed antibody does not have a cysteine at the first
position of at least one CDR3 region e.g., at least one of the VL CDR3 regions. Optionally,
the VL CDRl, VL CDR2 and VL CDR3 of the anti—FcRn antibody, tively, contain up to
amino acid tutions as compared to the ing sequences
(a) CDRl: TGTGSDVGSYNLVS (SEQ ID NO:l4)
(b) CDR2: GDSQRPS (SEQ ID NO:15)
(c) CDR3: SSYAGSGIYV (SEQ ID NO: 12), or GIYV (SEQ ID NO: 13).
Any of the anti—FcRn antibodies described above can further comprise a heavy chain
variable region (VH) that comprises a VH CDRl, a VH CDR2, and a VH CDR3, wherein the VH
CDR3 has at least 85% (e.g., at least 90% or 95%) homology with LAIGDSY (SEQ ID
NO:24). Optionally, the VH CDRl and VH CDR2 of the cRn antibody have at least
85% (e.g., at least 90% or 95%) homology with EYAMG (SEQ ID NO:22) and
SIGSSGGQTKYADSVKG (SEQ ID NO:23), respectively.
In some embodiments, the anti—FcRn antibody comprises a VH CDRl having at least
90% homology with EYAMG (SEQ ID NO:22), a VH CDR2 has at least 90% homology with
SIGSSGGQTKYADSVKG (SEQ ID NO:23), and/or a VH CDR3 has at least 90% homology
with LAIGDSY (SEQ ID NO:24). In one example, the cRn antibody comprises the VH
CDRl region EYAMG (SEQ ID NO:22), the VH CDR2 region SIGSSGGQTKYADSVKG
(SEQ ID NO:23), and/or the VH CDR3 region LAIGDSY (SEQ ID .
In other embodiments, the anti—FcRn antibody disclosed herein comprises a VH that
share at least 85% (e.g., at least 90%, 95%, or 98%) sequence identity to SEQ ID NO:9. In
one example, the VH of the isolated antibody comprises the amino acid sequence of SEQ ID
NO:9.
In another aspect, the present disclosure provides an isolated anti—FcRn antibody
comprising a heavy chain that comprises a heavy chain le region (VH) and a heavy
chain constant region, wherein the VH comprises a CDR3 region having at least 85% (e. g., at
least 90% or 95%) homology with LAIGDSY (SEQ ID NO:24) and the constant region has a
deletion at the position corresponding to the C—terminal lysine residue of SEQ ID NO: 17. In
some examples, the heavy chain variable of this cRn antibody further comprises a VH
CDRl and a VH CDR2, which have at least 85% (e. g., at least 90% or 95 %) homology with
EYAMG (SEQ ID NO:22), and SIGSSGGQTKYADSVKG (SEQ ID NO:23), respectively.
In other examples, the heavy chain constant region of the anti-FcRn antibody
comprises the amino acid sequence of SEQ ID NO: 26.
The above-described anti-FcRn antibody can further comprise a light chain
variable region (VL) that comprises a VL CDR3 at least 85% (e.g., at least 90% or
95%) identical to that of DX-2504 (CSYAGSGIYV; SEQ ID NO:25) and, optionally,
a VL CDRl at least 85% (e.g., at least 90% or 95%) identical TGTGSDVGSYNLVS
(SEQ ID NO: 14) and a VL CDR2 at least 85% (e.g., at least 90% or 95%) cal to
GDSQRPS (SEQ ID NO: 15). In one example, the anti-FcRn dy comprises the
VL CDRl region VGSYNLVS (SEQ ID NO: 14), the VL CDR2 region
GDSQRPS (SEQ ID NO: 15), and/or the VL CDR3 region CSYAGSGIYV (SEQ ID
NO:25), SSYAGSGIYV (SEQ ID NO: 12), or ASYAGSGIYV (SEQ ID NO: 13). In
another example, the VL of the anti-FcRn antibody comprises the amino acid
sequence of SEQ ID NO:8, SEQ ID NO: 10, or SEQ ID NO: 11.
In one embodiment of the present invention there is provided an isolated
antibody comprising a light chain variable region (VL) and a heavy chain variable
region (VH), wherein the antibody binds to human FcRn; and n the VL
comprises: (i) a VL CDRl sing the amino acid sequence TGTGSDVGSYNLVS
(SEQ ID NO: 14), (ii) a VL CDR2 comprising the amino acid sequence S
(SEQ ID NO: 15), and (iii) a VL CDR3 comprising the amino acid sequence
SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSIYV (SEQ ID NO: 13), and the VH
comprises: (i) a VH CDR1 comprising the amino acid ce EYAMG (SEQ ID
NO: 22); (ii) a VH CDR2 comprising the amino acid sequence
SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) a VH CDR3 comprising the
amino acid sequence LAIGDSY (SEQ ID NO: 24).
In yet another ment of the present invention there is ed a isolated
antibody comprising a light chain variable region (VL), a heavy chain that comprises a
heavy chain variable region (VH) and a heavy chain constant region, wherein the
antibody binds to human FcRn; and wherein the VL comprises: (i) a VL CDRl
comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14), (ii) a
VL CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15), and (iii)
a VL CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO: 25),
SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSIYV (SEQ ID NO: 13), and the VH
ses: (i) a VH CDR1 comprising the amino acid sequence EYAMG (SEQ ID
NO: 22); (ii) a VH CDR2 comprising the amino acid sequence comprising the amino
acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) VH CDR3
comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and the CH has a
deletion corresponding to the C-terminal lysine residue at the last position of SEQ ID
NO: 17.
Any of the anti-FcRn antibodies bed above can bind human FcRn with a
iation constant (KD) of less than 10 nM. The cRn antibodies provided in
the present disclosure can be human or humanized antibodies, or non-immunogenic in
a human. For example, they can comprise a human antibody framework region.
Alternatively, the anti-FcRn antibodies can be murine antibodies. In other examples,
they can be chimeric antibodies.
In some embodiments, the anti-FcRn antibodies provided herein are fulllength
dies (comprising a Fc ). Alternatively, they can be antigen -
binding fragments such as Fab, F(ab)'2, Fv, or ScFv. When desired, the anti-FcRn
antibodies are monoclonal antibodies.
Also disclosed herein are (i) a pharmaceutical composition sing any of
the antibodies described herein and a pharmaceutically able carrier, (ii) an
ed nucleic acid comprising a sequence that encodes any of the antibodies
provided herein, (iii) a vector comprising any of the nucleic acids comprising a
sequence that s any of the antibodies provided herein, and (iv) a host cell
comprising the vector comprising any of the c acids comprising a sequence that
encodes any of the antibodies provided herein.
Any of the anti-FcRn antibodies described herein can be used to detect the
presence of an FcRn or modulate the activity of an FcRn, either in vivo or in vitro.
In one aspect, provide herein is a method of detecting an FcRn in a sample, the
method comprising: contacting the sample with any of the antibodies provided herein,
detecting an ction between the antibody and the FcRn if present.
In r aspect the present disclosure provides a method of detecting an FcRn in a
subject, the method comprising: administering to the subject any of the antibodies provided
herein, which can be conjugated with a detectable molecule such as an imaging label
(fluorescent or radioactive), and detecting an interaction n the antibody and the FcRn
if present.
In yet another aspect, the present sure provides a method of modulating an FcRn
activity, the method comprising: contacting an FcRn with any of the antibodies provided
herein thereby modulating the activity of the FcRn.
In one aspect the invention provides a method of ng an autoimmune disorder or
modulating the half life/levels of circulating IgG in a subject, the method comprising:
administering to the subject any of the antibodies provided herein in an amount ive to
treat the autoimmune disorder or to modulate the half life/levels of circulating IgG in the
subject..
Also within the scope of the present disclosure are (a) pharmaceutical compositions
for use in modulating the activity of an FcRn, modulating the half life/levels of circulating
IgG, and/or ng an autoimmune disorder in a subject in need thereof, wherein the
pharmaceutical compositions each comprise one of more of the anti—FcRn antibodies
described herein and a pharmaceutically acceptable carrier, (b) the use of any of the anti—
FcRn antibodies described herein for any of the just—noted purposes, and (c) the use of any of
the anti—FcRn antibodies for the manufacture of a medicament for modulating the activity of
FcRn, modulating the half life/levels of circulating IgG, and/or treating an autoimmune
disorder in a subject (e.g., a human t).
These and other aspects and embodiments of the invention are described in greater
detail below.
Each of the limitations of the invention can encompass various ments of the
invention. It is, therefore, anticipated that each of the limitations of the invention involving
any one element or combinations of ts can be included in each aspect of the invention.
This invention is not limited in its application to the details of construction and the
arrangement of components set forth in the following description or rated in the
gs. The invention is e of other embodiments and of being practiced or of being
carried out in s ways. Also, the phraseology and terminology used herein is for the
2012/040409
purpose of ption and should not be ed as limiting. The use of “including”,
“comprising”, or “having , ning , involving”, and variations thereof herein, is meant
to encompass the items listed thereafter and equivalents thereof as well as additional items.
BRIEF DESCRIPTION OF THE DRAWINGS
The figures are illustrative only and are not required for enablement of the invention
disclosed herein.
Figure I shows a Size Exclusion Chromatography (SEC) analysis of DX—2504, 532A—
X53—C02 and 532A-X54-B03;
Figure 2 shows an SDS—PAGE analysis of DX—2504, 532A—X53—C02 and 532A—X54—
B03;
Figure 3 shows the temperature ity of DX—2504, 532A—X53—C02 and 532A—X54—
B03;
Figure 4 shows the pH stability of DX—2504, 532A—X53—C02 and 532A—X54—B03;
Figure 5 shows the stability at pH 8.3 of DX—2504, 532A—X53—C02 and 532A—X54—
B03;
Figure 6 shows the ity towards chemical denaturation of DX—2504, 532A—X53—
C02 and 532A-X54-B03;
Figure 7 shows the kinetic analysis of the interaction of hFcRn at pH6 with
immobilized DX-2504, 532A-X53-C02 and 532A—X54—B03;
Figure 8 shows the c analysis of the interaction at pH7.5 of hFcRn with
immobilized DX-2504, 532A-X53-C02 and 532A—X54—B03;
Figure 9 shows the sequences of DX2504 (SEQ ID NO:8), 532A—X53—C02 (SEQ ID
NO:lO), and 532A—X54-B03 (SEQ ID NO:ll).
Figure 10 shows the anti—hFcRn H—CDR3 vs. 0 length distributions.
Figure ll shows two graphs characterizing some of the properties of selected anti—
FcRn binding proteins.
Figure 12 shows the effect of anti—FcRn antibodies on the catabolism of hIgG in
TG32B mice.
Figure 13 shows serum concentrations of DX—2504 and DX—2507 administered to
cynomolgus monkeys.
Figure 14 shows IgG levels in cynomolgus monkeys following administration of DX—
2504 and DX—2507.
DETAILED DESCRIPTION OF THE INVENTION
Disclosed herein are isolated antibodies capable of binding to human FcRn and uses
thereof in detecting ce of FcRn, modulating FcRn activity, regulating the ife/level
of circulating IgGs, and/or treating disorders associated with IgG abnormality, such as
autoimmune disorders (e.g., multiple sclerosis, rheumatoid arthritis, lupus, immune
thrombocytopenia, ankylosing spondylitis, and pemphigus), and inflammatory ers such
as inflammatory bowel disease. Preferably, such anti—FcRn antibodies can (a) block the
binding of non—specific human IgG/Fc portion to the c interacting site; (b) bind to
both human and rat FcRn (soluble and cells); (c) bind to FcRn at pH 6; and/or (d) not
exclusively bind to BZM.
In normal stances, FcRn can extend the half—life of circulating IgG. Antibodies
that bind to FcRn can be used to modulate FcRn function, for example, by preventing its
interaction with IgG. In particular, antibodies that block FcRn interaction with IgG can be
used to reduce the half—life of IgG molecules.
In one aspect, the disclosure provides, inter alia, human antagonistic anti—human
FcRn antibodies that are available for the treatment of autoimmune disorders and reduction of
circulating levels of IgGs. Also sed are high affinity e Fabs (sFab) with the
ability to bind through the antigen binding domain and block the ction between IgG—Fc
and human FcRn or rat FcRn.
Definitions
The term “binding protein” refers to a n that can interact with a target molecule.
This term is used interchangeably with “ligand.” An “FcRn—binding protein” or
binding ligand” refers to a protein that can interact with an FcRn, and includes, in
particular, proteins that preferentially interact with an FcRn, e.g. , IgG.
As used herein, the term “antibody” refers to a protein that includes at least one
immunoglobulin variable domain or immunoglobulin variable domain sequence. For
example, an antibody can include a heavy (H) chain le region (abbreviated herein as
VH), and a light (L) chain le region (abbreviated herein as VL). In another example, an
antibody includes two heavy (H) chain variable regions and two light (L) chain variable
regions. The term “antibody” encompasses antigen—binding fragments of antibodies (e. 57.,
single chain antibodies, Fab and sFab fragments, F(ab')2, Fd fragments, Fv fragments, scFv,
and dAb fragments) as well as complete antibodies length antibodies).
The VH and VL regions can be further subdivided into regions of hypervariability,
termed “complementarity determining regions” (“CDR”), interspersed with regions that are
more conserved, termed “framework regions” ("FR"). The extent of the framework region
and CDR's has been precisely defined (see, Kabat, E.A., et al. (1991) Sequences ofProteins
ofImmunological Interest, Fifth n, US. Department of Health and Human es,
NIH Publication No. 91—3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901—917, see
also /www.hgmp.mrc.ac.uk). Kabat definitions are used . Each VH and VL is
typically composed of three CDR’s and four FR’s, arranged from amino—terminus to carboxy—
terminus in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, FR4.
The term “antigen—binding fragment” of a full length antibody (or simply “antibody
portion,” or “fragment”), as used , refers to one or more fragments of a full—length
antibody that retain the ability to specifically bind to a target of interest. Examples of binding
fragments encompassed within the term “antigen—binding fragment” of a full length antibody
include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1
domains; (ii) a F(ab')2 fragment, a bivalent fragment ing two Fab fragments linked by a
ide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1
domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an
antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544—546), which consists of a
VH domain; and (vi) an isolated complementarity determining region (CDR) that retains
functionality. Furthermore, although the two domains of the Fv fragment, VL and VH, are
coded for by separate genes, they can be joined, using inant methods, by a synthetic
linker that enables them to be made as a single protein chain in which the VL and VH s
pair to form monovalent molecules known as single chain Fv (scFv). See e. 57., Bird et al.
(1988) Science 3—426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879—
5883.
Antibody fragments can be obtained using any riate technique including
conventional techniques known to those with skill in the art. The term “monospecific
antibody” refers to an antibody that displays a single binding specificity and affinity for a
ular target, e. g., epitope. This term includes a “monoclonal antibody” or “monoclonal
antibody composition,” which as used herein refer to a preparation of antibodies or fragments
thereof of single molecular composition. As used herein, “isotype” refers to the antibody
class (e.g., IgM or IgGl) that is encoded by heavy chain constant region genes.
As used herein, “binding affinity” refers to the apparent association constant or Ka.
The Ka is the reciprocal of the dissociation constant (Kd). A g protein may, for
example, have a binding affinity of at least 105, 106, 10'7 ,10'8, 109, 10'10 and 10'11 M for a
ular target molecule. Higher affinity binding of a binding ligand to a first target relative
to a second target can be indicated by a higher Ka (or a smaller numerical value Kd) for
binding the first target than the Ka (or numerical value Kd) for binding the second target. In
such cases, the g protein has icity for the first target (e.g., a protein in a first
conformation or mimic thereof) relative to the second target (e.g., the same protein in a
second conformation or mimic f; or a second protein). Differences in binding affinity
(e.g., for specificity or other isons) can be at least 1.5, 2, 3, 4, 5, 10, 15, 20, 50, 70, 80,
100, 500, 1000, or 105 fold.
Binding affinity can be determined by a variety of methods including equilibrium
dialysis, equilibrium binding, gel filtration, ELISA, e plasmon resonance, or
spectroscopy (e.g., using a fluorescence assay). Exemplary ions for evaluating binding
affinity are in PBS (phosphate buffered saline) at pH 7.2 at 30°C. These techniques can be
used to measure the concentration of bound and free binding protein as a function of binding
protein (or target) concentration. The concentration of bound binding protein ([Bound]) is
related to the concentration of free binding protein ([Free]) and the concentration of binding
sites for the binding protein on the target Where (N) is the number of g sites per target
molecule by the following equation:
[Bound] = N - [Free]/((l/Ka) + [Free]).
It is not always necessary to make an exact determination of Ka, though, since
sometimes it is sufficient to obtain a quantitative measurement of affinity, e.g., determined
using a method such as ELISA or FACS analysis, is tional to Ka, and thus can be used
for comparisons, such as determining r a higher affinity is, 6.57., 2—fold , to
obtain a qualitative measurement of affinity, or to obtain an inference of affinity, 6.57., by
activity in a functional assay, 6.57., an in vitro or in vivo assay.
The term “cognate ligand” refers to a naturally occurring ligand of an FcRn, including
naturally occurring variants thereof (e.g., splice variants, naturally occurring mutants, and
isoforms).
A “conservative amino acid substitution” is one in which the amino acid e is
replaced with an amino acid residue having a similar side chain. Families of amino acid
residues having similar side chains have been d in the art. These families include
amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g.,
aspartic acid, ic acid), uncharged polar side chains (e.g., e, asparagine,
glutamine, , threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine,
leucine, isoleucine, e, phenylalanine, methionine, tryptophan), beta—branched side
chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine,
phenylalanine, tryptophan, histidine). It is possible for many framework and CDR amino
acid residues to include one or more conservative tutions.
Consensus sequences for biopolymers can include positions which can be varied
among various amino acids. For example, the symbol “X” in such a context generally refers
to any amino acid (e.g., any of the twenty natural amino acids or any of the nineteen non—
cysteine amino acids). Other allowed amino acids can also be indicated for example, using
parentheses and slashes. For example, “(A/W/F/N/Q)” means that alanine, phan,
phenylalanine, asparagine, and glutamine are allowed at that particular position.
An “effectively human” globulin variable region is an immunoglobulin
variable region that includes a sufficient number of human framework amino acid positions
such that the immunoglobulin variable region does not elicit an immunogenic response in a
normal human. An “effectively human” antibody is an antibody that includes a sufficient
number of human amino acid positions such that the antibody does not elicit an immunogenic
response in a normal human.
An “epitope” refers to the site on a target nd that is bound by a binding
protein (e.g., an antibody such as a Fab or full length antibody). In the case where the target
compound is a protein, the site can be ly composed of amino acid components, entirely
composed of chemical modifications of amino acids of the n (e.g., glycosyl moieties),
or composed of combinations thereof. Overlapping epitopes e at least one common
amino acid residue.
Calculations of “homology” or “sequence identity” between two sequences (the terms
are used interchangeably herein) are med as follows. The sequences are aligned for
optimal comparison es (e.g., gaps can be introduced in one or both of a first and a
second amino acid or nucleic acid sequence for optimal alignment and mologous
sequences can be disregarded for comparison purposes). The optimal alignment is
determined as the best score using the GAP program in the GCG software package with a
Blosum 62 scoring matrix with a gap penalty of 12, a gap extend y of 4, and a
frameshift gap penalty of 5. The amino acid residues or nucleotides at corresponding amino
acid positions or nucleotide positions are then compared. When a position in the first
sequence is occupied by the same amino acid residue or nucleotide as the corresponding
position in the second sequence, then the molecules are identical at that position (as used
herein amino acid or nucleic acid “identity” is equivalent to amino acid or c acid
“homology”). The percent identity between the two sequences is a on of the number of
identical positions shared by the sequences.
In one embodiment, the length of a reference sequence aligned for ison
purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, 80%, 90%,
92%, 95%, 97%, 98%, or 100% of the length of the reference sequence. For example, the
reference sequence may be the length of the globulin variable domain ce.
A “humanized” immunoglobulin variable region is an immunoglobulin variable
region that is modified to e a sufficient number of human ork amino acid
positions such that the immunoglobulin variable region does not elicit an immunogenic
response in a normal human. Descriptions of “humanized” immunoglobulins include, for
example, US 6,407,213 and US 5,693,762.
As used herein, the term “hybridizes under low stringency, medium stringency, high
stringency, or very high stringency conditions” describes conditions for hybridization and
washing. Guidance for ming hybridization reactions can be found in Current Protocols
in Molecular y, John Wiley & Sons, NY. (1989), 6.31—6.36, which is incorporated by
reference. Aqueous and non—aqueous methods are described in that reference and either can
be used. Specific hybridization ions referred to herein are as follows: (1) low
stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) at about
45°C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of
the washes can be increased to 55°C for low stringency conditions); (2) medium stringency
hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X
SSC, 0.1% SDS at 60°C; (3) high stringency hybridization ions in 6X SSC at about
45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C; and (4) very high
stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed
by one or more washes at 0.2X SSC, 1% SDS at 65°C. Very high stringency conditions (4)
are the preferred conditions and the ones that should be used unless otherwise specified. The
disclosure includes nucleic acids that hybridize with low, medium, high, or very high
stringency to a c acid described herein or to a complement thereof, e.g., c acids
encoding a g protein described herein. The nucleic acids can be the same length or
within 30, 20, or 10% of the length of the reference nucleic acid. The nucleic acid can
correspond to a region encoding an globulin variable domain sequence.
An FcRn g protein may have mutations (e.g., at least one, two, or four, and/or
less than 15, 10, 5, or 3) relative to a binding protein described herein (e.g., a conservative or
non—essential amino acid substitutions), which do not have a substantial effect on the protein
functions. Whether or not a particular substitution will be tolerated, i.e. will not adversely
affect biological properties, such as binding activity can be ted, e. 57., using the method
of Bowie, et al. (1990) Science 247:1306—1310.
An “immunoglobulin domain” refers to a domain from the variable or nt
domain of immunoglobulin molecules. oglobulin domains typically contain two B—
sheets formed of about seven B—strands, and a conserved disulphide bond (see, e. g., A. F.
ms and A. N. Barclay 1988 Ann. Rev Immunol. 6:381—405).
As used herein, an “immunoglobulin variable domain sequence” refers to an amino
acid sequence which can form the structure of an immunoglobulin variable domain such that
one or more CDR regions are positioned in a conformation suitable for an n binding
site. For example, the sequence may include all or part of the amino acid sequence of a
naturally—occurring variable domain. For example, the sequence may omit one, two or more
N— or C—terrninal amino acids, internal amino acids, may include one or more insertions or
onal terminal amino acids, or may include other alterations. In one embodiment, a
polypeptide that includes immunoglobulin variable domain sequence can associate with
another immunoglobulin variable domain sequence to form a target binding structure (or
en binding site”), e.g., a structure that preferentially interacts with an FcRn structure.
The VH or VL chain of the antibody can further include all or part of a heavy or light
chain constant region, to y form a heavy or light immunoglobulin chain, respectively.
In one embodiment, the antibody is a tetramer of two heavy globulin chains and two
light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are inter—
ted by, e.g. disulfide bonds. The heavy chain constant region includes three domains,
CH1, CH2 and CH3. The light chain constant region includes a CL domain. The variable
region of the heavy and light chains contains a binding domain that interacts with an antigen.
The constant regions of the antibodies typically mediate the g of the antibody to host
tissues or factors, ing various cells of the immune system (e.g., effector cells) and the
first component (Clq) of the classical complement system. The term “antibody” includes
intact immunoglobulins of types IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof). The
light chains of the globulin may be of types: kappa or lambda. In one embodiment,
the antibody is ylated. An antibody can be onal for antibody—dependent
cytotoxicity and/or complement—mediated cytotoxicity.
One or more regions of an antibody can be human or effectively human. For
e, one or more of the variable regions can be human or effectively human. For
example, one or more of the CDRs can be human, e.g., HC CDRl, HC CDR2, HC CDR3, LC
CDRl, LC CDR2, and LC CDR3. Each of the light chain CDRs can be human. HC CDR3
can be human. One or more of the framework regions can be human, e.g., FRl, FR2, FR3,
and FR4 of the HC or LC. In one embodiment, all the framework regions are human, e.g.,
derived from a human somatic cell, e.g. a hematopoietic cell that es immunoglobulins
or a non—hematopoietic cell. In one embodiment, the human sequences are germline
sequences, e.g., encoded by a germline nucleic acid. One or more of the constant regions can
be human or effectively human. In one embodiment, at least 70, 75, 80, 85, 90, 92, 95, or
98% of, or the entire of, the dy can be human or effectively human.
All or part of an antibody can be encoded by an immunoglobulin gene or a segment
thereof. Exemplary human immunoglobulin genes include the kappa, lambda, alpha (IgAl
and IgA2), gamma (IgGl, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as
well as the myriad immunoglobulin variable region genes. Full—length immunoglobulin
“light chains” (about 25 KDa or 214 amino acids) are encoded by a variable region gene at
the NH2—terminus (about 110 amino acids) and a kappa or lambda constant region gene at the
COOH——terminus. Full—length immunoglobulin “heavy chains” (about 50 KDa or 446 amino
acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of
the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino
acids).
An ted composition” refers to a ition that is d from at least 90%
of at least one component of a natural sample from which the isolated composition can be
obtained. Compositions produced artificially or naturally can be “compositions of at least” a
n degree of purity if the species or population of species of interests is at least 5, 10, 25,
50, 75, 80, 90, 92, 95, 98, or 99% pure on a weight—weight basis.
The term “mimic,” in the context of a mimic of a conformation of an FcRn or portion
thereof, refers to a modified FcRn which has a bias for at least one particular conformation
ve to a naturally occurring FcRn, or portion thereof.
A “non—essential” amino acid residue is a residue that can be d from the wild—
type sequence of the binding agent, 6.57., the antibody, without abolishing or without
ntially altering a biological activity, whereas an “essential” amino acid residue results
in such a .
The phrases “parenteral administration” and “administered parenterally” as used
herein means modes of administration other than enteral and topical administration, usually
by injection, and includes, without limitation, intravenous, intramuscular, rterial,
intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural
and intrasternal injection and infusion.
The terms “polypeptide” or “peptide” (which may be used interchangeably) refer to a
polymer of three or more amino acids linked by a peptide bond, 6.57., between 3 and 30, 12
and 60, or 30 and 300, or over 300 amino acids in length. The polypeptide may include one
or more unnatural amino acids. Typically, the ptide includes only natural amino acids.
A “protein” can include one or more polypeptide chains. ingly, the term “protein”
asses polypeptides. A protein or polypeptide can also include one or more
modifications, 6.57., a glycosylation, amidation, phosphorylation, nitrosylation, and so forth.
The term “small peptide” can be used to describe a polypeptide that is between 3 and 30
amino acids in length, e. 57., between 8 and 24 amino acids in length.
A “prophylactically effective ” refers to an amount effective, at dosages and
for periods of time necessary, to achieve the desired prophylactic result. Typically, because a
prophylactic dose is used in subjects prior to or at an earlier stage of disease, the
prophylactically ive amount will be less than the therapeutically effective amount.
As used herein, the term “substantially identical” (or “substantially homologous”) is
used herein to refer to a first amino acid or c acid sequence that contains a sufficient
number of identical or equivalent (e.g., with a similar side chain, e.g., ved amino acid
substitutions) amino acid residues or tides to a second amino acid or nucleic acid
sequence such that the first and second amino acid or nucleic acid sequences have (or encode
proteins having) similar activities, e.g., a binding activity, a g preference, or a
biological activity. In the case of antibodies, the second antibody has the same specificity
and has at least 50% of the affinity relative to the same antigen.
Sequences similar or homologous (e.g., at least about 85% sequence identity) to the
sequences disclosed herein are also part of this application. In some embodiments, the
sequence identity can be about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99% or higher. In addition, substantial identity eXists when the nucleic acid segments
hybridize under selective hybridization conditions (e.g., highly ent hybridization
conditions), to the complement of the . The nucleic acids may be present in whole
cells, in a cell lysate, or in a partially purified or substantially pure form.
Statistical significance can be determined by any art known method. Exemplary
statistical tests include: the Students T—test, Mann Whitney U rametric test, and
Wilcoxon non—parametric statistical test. Some statistically significant onships have a P
value of less than 0.05 or 0.02. Particular binding proteins may show a difference, 6.57., in
specificity or binding, that are tically icant (e.g., P value < 0.05 or 0.02). The
terms “induce”, “inhibit”, “potentiate”, “elevate”, “increase”, “decrease” or the like, 6.57.,
which denote distinguishable qualitative or quantitative differences between two states, and
may refer to a difference, 6.57., a statistically significant difference, between the two states.
A “therapeutically effective dosage” modulates a able parameter, e.g., levels of
circulating IgG antibodies by a statistically significant degree or at least about 20%, by at
least about 40%, by at least about 60%, or by at least about 80% relative to untreated
subjects. The y of a compound to modulate a measurable parameter, e.g.,
autoimmunity, can be evaluated in an animal model system tive of efficacy in human
autoimmune disorders. Alternatively, this property of a composition can be evaluated by
2012/040409
examining the ability of the compound to modulate a parameter in vitro, 6.57., by assays
known to the skilled practitioner.
Other features and advantages of the instant invention will become more apparent
from the following detailed description and claims. Embodiments of the invention can
include any combination of features described . In no case does the term
“embodiment” exclude one or more other features disclosed herein.
FcRn Sequences
The following sequence alignment is of a human FcRn alpha chain amino acid
sequence with a rat FcRn alpha chain amino acid sequence An exemplary FcRn protein can
include one of these two sequences, or a fragment thereof, e.g., a fragment without the signal
sequence:
Signal Sequence 0L1 domain
a_HUMAN: MGVPRPQPWALGLLLFLLPGSLG A78H-S.LYH.TAVSSPAPGTPAFWVSGW.GPQQY.SJ.
a_RAT: MGMSQPGV-LLSLLLVLLPQTWG AdPR-P.MYH.AAVSDLSTGLPSFWATGW.GAQQY.TJ.
0L1 domain 0L2 domain
a_HUMAN: YNS.RGfiAfiPCGAWVWENQVSWYWfiKfiiiD.RIKfiK.b.fiAbKA.GGK——GP YT-QG..G
a_RAT: YNN.RQHADPCGAWIWENQVSWYWfiKfiiiD.KSKfiQ.b.fiAIRi.fiNQINGi*J bi-QG..G
0L2 domain
a_HUMAN: Cm.GPDNLSVPLAKbA.NGfifibMNbDLKQGLWGGDWPEALAISQRWQQQD<AANK?LTF.
a_RAT: C'.APDNSSLPLAVbA.NGfifibMRbNPRiGNWSGfiWPfiiDIVGNLWMKQPfiAARKfiSfit._*J
0L2 domain 0L3 domain
a_HUMAN: JFSCPiR.RfiH.fiRGRGN.fiWK fiPPSMR.KARPSSPGFSVJTCSAFSFYPP?.QLRF-RN
a_RAT: R.LGH.?RGRQN.fiWK .KARPGNSGSSVJTCAAFSFYPP?.KFRF.RN
0L3 domain
a_HUMAN: GJAAGTGQGDFGPNSDGSFHASSSJTVKSGDEHHYCCIVQHAG.AQP.RVfi.fi
a_RAT: GNCSTGPNGDGSFHAWSL.fiVKRGDfiHHYQCQVfiHfiG.AQP.TVD.D
Transmembrane Cytop asm c domain
G_HUMAN: VLVVGIVIGV..LTAAAVGGA..W RRMRSGAPAPWISJRGDDTGV..PTPGWAQJ.
a_RAT: SPARSSVPVVGIILGL.-VVVAIAGGV..W NRMRSG-PAPWLS-SGDDSGD..PGGN.PP
a_HUMAN: VNVIPAIA (SEQ ID NO:1)
a_RAI: fiAfiPQGVNAFPAIS (SEQ ID NO:2)
The following sequence alignment is of a human [32 microglobulin amino acid
ce with a rat B2 microglobulin amino acid sequence. An exemplary FcRn protein can
e one of these two sequences, or a fragment thereof, 6.57., a fragment Without the signal
sequence:
Signal Sequence B2 microglobulin
BZm_human: MSRSVALAVLALLSLSGLEA IQRIPKIQVYSRHPAENGKSNFANCYVSGFHPSDIDVD..J.
B2m_rat : MARSVTVIFLVLVSLAVVLA IQKIPQIQVYSRHPPENGKPNFJNCYVSQbHPPQIfiIfi..
BZ microglobulin
BZm_human: KNGfiRIfiKVfiHSD-SbSKDWSbYL.YYifibIPIfiKDfiYACRVNHVIJSQPKIVKWDRDM (S
ID NO:3)
B2m_rat : KNG<KIPNIfiMSD-SbSKDWSbYI.AHIfibIPIfiIDVYACRVKHVI.KVPKIVIWDRDM (S
ID NO:4)
An exemplary c acid sequence encoding an FcRn protein alpha chain can
include the following sequences:
FcRn alpha nucleotide sequence (Homo sapiens):
GITCIICAGGIACGAGGAGGGCAIIGIIGICAGICIGGACCGAGCCCGCAGAGCCCCICCICGGCGICCI
GGCCGIGCCCGCGGIGICCCGGGAGGAAGGGGCGGGCCGGGGGICGGGAGGAGICACGIGCCCC
CICCCGCCCCAGGICGICCiCiCAGCAIGGGGGiCCCGCGGCCICAGCCCIGGGCGCIGGGGCICCIGCI
CIITCICCIICCIGGGAGCCIGGGCGCAGAAAGCCACCTCICCCICCIGIACCACCIIACCGCGGIGICC
ICGCCIGCCCCGGGGACICCIGCCIICIGGGIGICCGGCIGGCIGGGCCCGCAGCAGIACCIGAGCIACA
AIAGCCIGCGGGGCGAGGCGGAGCCCIGIGGAGCIIGGGICIGGGAAAACCAGGIGICCIGGIAIIGGGA
GAAAGAGACCACAGAICIGAGGAICAAGGAGAAGCTCIITCIGGAAGCIIICAAAGCIIIGGGGGGAAAA
GGICCCIACACTCIGCAGGGCCIGCIGGGCIGIGAACIGGGCCCIGACAACACCICGGIGCCCACCGCCA
AGIICGCCCIGAACGGCGAGGAGIICAIGAAIIICGACCICAAGCAGGGCACCIGGGGIGGGGACIGGCC
CGAGGCCCIGGCTATCAGICAGCGGIGGCAGCAGCAGGACAAGGCGGCCAACAAGGAGCICACCIICCIG
CTATTCICCIGCCCGCACCGCCIGCGGGAGCACCIGGAGAGGGGCCGCGGAAACCIGGAGIGGAAGGAGC
CCCCCICCAIGCGCCIGAAGGCCCGACCCAGCAGCCCIGGCIIIICCGIGCIIACCIGCAGCGCCIICIC
CITCIACCCICCGGAGCIGCAACIICGGIICCIGCGGAAIGGGCIGGCCGCIGGCACCGGCCAGGGIGAC
IICGGCCCCAACAGIGACGGAICCIICCACGCCICGICGICACIAACAGICAAAAGIGGCGAIGAGCACC
ACIACIGCIGCAIIGIGCAGCACGCGGGGCIGGCGCAGCCCCICAGGGIGGAGCIGGAAICICCAGCCAA
GICCiCCGiGCiCGiGGiGGGAAiCGiCAiCGGIGICiiGCiACiCACGGCAGCGGCIGIAGGAGGAGCI
CIGIIGIGGAGAAGGAIGAGGAGIGGGCIGCCAGCCCCIIGGAICICCCIICGIGGAGACGACACCGGGG
IGCCCACCCCAGGGGAGGCCCAGGAIGCIGAIIIGAAGGAIGIAAAIGIGAIICCAGCCACCGC
CIGACCAICCGCCAIICCGACIGCIAAAAGCGAAIGIAGICAGGCCCCIIICAIGCIGIGAGACCICCIG
GAACACIGGCAICICIGAGCCICCAGAAGGGGiiCiGGGCCiAGiiGiCCiCCCiCiGGAGCCCCGICCI
40 GIGGICIGCCICAGIiiCCCCiCCiAAIACAIAIGGCIGIIIICCACCICGAIAAIAIAACACGAGIIIG
GGCCCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA (S?Q ID NO:5)
WO 67039
The nucleic acid e of an exemplary human FcRn —cellular domain) plus
GPI DNA sequences (lowercase bold) is set forth below.
ATGGGGGTCCCGCGGCCTCAGCCCTGGGCGCJGGGGCJCCJGCJCJJJCJCCJJCCJGGGAGCCTGGGCG
CAGAAAGCCACCTCTCCCTCCTGTACCACCTTACCGCGGTGTCCTCGCCTGCCCCGGGGACTCCTGCCTT
CTGGGTGTCCGGCTGGCTGGGCCCGCAGCAGTACCTGAGCTACAATAGCCTGCGGGGCGAGGCGGAGCCC
TGTGGAGCTTGGGTCTGGGAAAACCAGGTGTCCTGGTATTGGGAGAAAGAGACCACAGATCTGAGGATCAA
GGAGAAGCTCTTTCTGGAAGCTTTCAAAGCTTTGGGGGGAAAAGGTCCCTACACTCTGCAGGGCCTGCTGG
GCTGTGAACTGGGCCCTGACAACACCTCGGTGCCCACCGCCAAGTTCGCCCTGAACGGCGAGGAGTTCATG
AATTTCGACCTCAAGCAGGGCACCTGGGGTGGGGACTGGCCCGAGGCCCTGGCTATCAGTCAGCGGTGGCA
GCAGCAGGACAAGGCGGCCAACAAGGAGCJCACCJJCCJGCJAJJCJCCJGCCCGCACCGCCTGCGGGAGC
ACCTGGAGAGGGGCCGCGGAAACCTGGAGTGGAAGGAGCCCCCCTCCATGCGCCTGAAGGCCCGACCCAGC
AGCCCTGGCTTTTCCGTGCTTACCTGCAGCGCCTTCTCCTTCTACCCTCCGGAGCTGCAACTTCGGTTCCT
GCGGAATGGGCTGGCCGCTGGCACCGGCCAGGGTGACTTCGGCCCCAACAGTGACGGATCCTTCCACGCCT
CGTCGTCACTAACAGTCAAAAGTGGCGATGAGCACCACTACTGCTGCATTGTGCAGCACGCGGGGCTGGCG
CAGCCCCTCAGGGTGGAGCTGGAATCTCCAGCCAAGTCCTCCcggccgctcgacgggctacgagcatcagt
actaggcgcaggcctactactatcactactaccagcactactacgatttgggccataa (SEQ ID
NO:6)
An exemplary nucleic acid sequence encoding a Beta—2—microglobulin (BZM) can
include the following sequences:
Beta—2—microglobulin (BZM) nucleotide (Homo sapiens):
AGTGGAGGCGTCGCGCTGGCGGGCATTCCTGAAGCTGACAGCATTCGGGCCGAGATGTCTCGCT
CCGJGGCCJJAGCJGJGCJCGCGCJACJCJCJCJiJCJGGCCiGGAGGCTATCCAGCGTACTCCAAAGAT
TCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAAGJCAAAJJJCCJGAAJJGCJAJGJGJCJGGGJii
CATCCATCCGACATTGAAGTTGACTTACTGAAGAATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGACT
TGTCTTTCAGCAAGGACJGGJCJJJCJAJCJCJJGJACJACACJGAAJJCACCCCCACTGAAAAAGATGA
GTATGCCTGCCGTGTGAACCATGTGACTTTGTCACAGCCCAAGATAGTTAAGTGGGATCGAGACATGTAA
GCAGCATCATGGAGGTTTGAAGATGCCGCAJJJGGAJJGGAJGAAJJCCAAAJJCJGCJJGCJJGCJJJJ
. JGAJAJGCJ. JAJACACJ. JACACJ. J. JAJGCACAAAAJGJAGGGJ. JAJAAJAAJGJ. JAACAJGGAC
AJGAJCJ. J.CJ. J. JAJAAJ. JCJACJ. J. JGAGJGCJGJCJCCAJGJ J. JGAJGJAJCJGAGCAGGTTGCTCCACA
GGTAGCTCTAGGAGGGCTGGCAACTTAGAGGTGGGGAGCAGAGAATTCTCTTATCCAACATCAACATCTT
GGJCAGAJiJGAACJCJJCAAJCJCJJGCACJCAAAGCJJGJJAAGAJAGJJAAGCGJGCAJAAGJJAAC
JJCCAAJJJACAJACJCJGCJJAGAAJJJGGGGGAAAATTTAGAAATATAATTGACAGGATTATTGGAAA
TTTGTTATAATGAATGAAACAJiiJGJCAJAJAAGAJJCAJAJJJACJJCJJAJACAJJJGAJAAAGJAA
GGCAJGGJ. JGJGGJ. JAAJCJGGJ. J. JAJ. J. J. J. JGJ. JCCACAAGJ. JAAAJAAAJCAJAAAACJ. JGAJGJGJ. JA
TCTCTTA (SEQ ID NO:7)
FcRn binding dies
40 DX2504 is an FcRn binding antibody that is described in W02009/131702 and US—
2009—0324614—Al. Both W02009/131702 and US—2009—03246l4—Al are orated by
reference into this application in their entirety. DX2504 was generated by a combination of
monoclonal antibody technology and phage display experiments using FcRn polypeptides or
cells expressing FcRn as the target. In addition, the sequence of DX2504 was ned to
45 lower immunogenicity. The sequences of DX2504 light chain and heavy chain are shown
below:
Light chain Variable Region (SEQ ID NO:8):
FRl—L CDRl—L FR2—L CDR2—L
QSALTQPASVSGSPGQSITISC TGTGSDVGSYNLVS WYQQHPGKAPKLMIY GDSQRPS
FR3—L CDR3—L FR4—L
GVSNRFSGSKSGNTASLTISGLQAfiDfiADYYC CSYAGSGIYV VTVL
Light Chain Full Length (SEQ ID NO: 16; CL underlined):
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNJVSWYQQHPGKAPKLMIYGDSQRPSGVSNRFSGSKSGNTASL
TISGLQAfiDfiADYYCCSYAGSGIYVFGTGTKVTVLGQPKANPIViLbPPSSfinLQAVKATLVCJISDFYPGAVTV
AWKADGSPV{AGVETTKPSKQSNNKYAASSYLS.TPVQWKSHRSYSCQVIHfiGSIVfiKiVAPILCS
Heavy chain Variable Region (SEQ ID NO:9):
FRl—H CDRl—H FRZ—H CDR2—H
fiVQLLflSGGGLVQPGGSLRDSCAASGFTFS EYAMG WVRQAPGKGLEWVS SIGSSGGQTKYADSVKG
FR3—H CDR3—H FR4—H
RFTISRDNSKNTLYLQMNS.RAVDTAVYYCAR LAIGDSY WGQGTMVTVSS
Heavy Chain Full :Length (SEQ ID NO: 17; CH underlined)
fiVQ.LfiSGGG.VQPGGSLRLSCAASGFTFSEYAMGWVRQAPG{GLEWVSSIGSSGGQTKYADSV<GRFTISRDNS
<NT-Y-Q DTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSS{STSGGTAALGCLVKDYFP
EPVTVSWWSGAATSGV{TFPAVLQSSGLYSJSSVVTVPSSSLGTQTYICNVNH{PSWTKVDKRVEP{SCDKTHTC
PPCPAP?.LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHfiDPfiVKbNWYVDGVLVHNAKIKPRfifiQYNSIYR
VVSVLTV.HQDWLWGKVYKCKVSNKALPAPIEKTISKAKGQPRfiPQVYILPPSRun iKNQVSLTCAVKGFYPSD
IAVfiWfiSWGQPfiNWYKIIPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHVA.{NHYTQKS.S-SPGK
In addition to binding FcRn, DX2504, or precursor antibodies, has been shown to
block the binding of IgG—Fc to FcRn expressing cells (Example 21 of /131702).
Furthermore, administering DX2504 to Tg32B mice, a mouse in which the mouse FcRn is
replaced by the human FcRn, lowered the levels of a human IgG which was administered to
the mice previously (Example 27 of /131702). Moreover, the administration of
DX2504 in cynomolgus monkeys resulted in the lowering of IgG serum levels (Example 27
of WO2009/l3 1702).
It was unexpectedly found herein that altering either the CDR3 of the light chain (e.g.,
the cysteine mutants bed herein) or the constant region of the heavy chain (e.g., the
deletion s described herein) of DX2504 resulted in FcRn g antibodies with
improved properties when compared to DX2504. This finding was unexpected at least in part
because, generally, an antibody that has gone through as many rounds of sequence
optimization, such as DX2504, cannot be easily zed further by introducing additional
mutations.
Cysteine Mutants
The cysteine mutants of DX2504 described herein lack a cysteine e at the first
position of at least one CDR3, for example, the first on of the VL CDR3 of DX2504
being replaced with another amino acid residue such as Ala, Ser, or a conservative
tution thereof. Exemplary cysteine mutants include, but are not limited to, 532A—X53—
C02 (having a VL set forth as SEQ ID NO: 10) and 532A—X53—B03 (having a VL set forth as
SEQ ID NO: 1 1). Such mutants preserve the FcRn—binding activity, e.g., binding to human
FcRn with a dissociation constant (KD) of less than 10 nM, which can be determined by a
e method. In some examples, the cysteine mutant contains two VL chains, either one or
both of which do not have a cysteine at the first position of the VL CDR3 region.
The cysteine mutant described herein can comprise a VL chain, in which the CDRl,
CDR2, and CDR3 share at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%) sequence
identity to the VL CDRl and VL CDR2 of DX2504 (SEQ ID NOs: l4 and 15, tively;
identical to those in 532A—X53—C02 or 532A—X53—B03) and an altered VL CDR3 of DX2504
(SEQ ID NO:l2 or 13, the VL CDR3 of 532A—X53—C02 or 532A—X53—B03). In some
embodiments, one or more of the VL CDRs share at least 70% sequence identity to that of the
corresponding CDR(s) of 532A—X53—C02 or 532A—X53—B03. For example, the cysteine
mutant has at least 70% homology (at least 75%, 80%, 85%, 90%, or 95%) in the VL CDR3
region with the sequences SSYAGSGIYV (SEQ ID NO: 12), or ASYAGSGIYV (SEQ ID
NO: 13).
In other embodiments, the VL CDRs of the cysteine mutant, in combination, share at
least 70% sequence identity to those of 532A—X53—C02 or 532A—X53—B03, in ation.
For example, an antibody with at least 90% homology in the CDRl, CDR2 and CDR3 region
with the reference CDR sequences refers to an antibody that has at least 9 out of every 10
amino acids in the combined CDRl, CDR2 and CDR3 regions identical to the amino acids
found in the combined CDRl, CDR2 and CDR3 regions of 532A—X53—C02.
Alternatively, the antibody can have up to 1, up to 2, up to 3, up to 4, or up to 5 amino
acid tutions in the VL CDR3 region as compared to the sequences SSYAGSGIYV (SEQ
ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13). In some embodiments, the cysteine mutant
can n up to 3 substitutions in the VL CDR3 region as compared to the CDR3 region of
2012/040409
DX2504. The one or more of the amino acids substitutions can be vative amino acid
substitutions.
Moreover, the cysteine mutant antibodies can have up to 1, up to 2, up to 3, up to 4,
up to 5, up to 6, up to 7, up to 8, up to 9, up to 10, or up to 15 amino acid substitutions in the
CDR1, CDR2 and CDR3 region as compared to the sequences of the CDR1, CDR2 and
CDR3 regions of 532A—X53—C02 or 532A—X53—B03. In some embodiments, they can n
up to 10 substitutions in the VL CDR1, CDR2, and CDR3 regions collectively. In one
example, the one or more of the amino acids substitutions are conservative amino acid
substitutions.
In some embodiments, the cysteine mutant comprises a VL chain that share at least
70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 97%, or 98%) sequence identity to the VL
sequence of 532A—X53—C02 (SEQ ID NO:lO) or that of 532A—X53—B03 (SEQ ID NO:ll). In
one example, the cysteine mutant comprises the same VL CDR3 region as 532A—X53—C02 or
53—B03, and optionally, the same VL CDRl and CDR2 s as the two exemplary
mutants.
The “percent identity” of two amino acid sequences can be determined using the
algorithm of Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264—68, l990, modified as
in Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873—77, 1993. Such an algorithm is
incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. J.
Mol. Biol. 215:403—10, l990. BLAST protein searches can be performed with the XBLAST
program, score=50, wordlength=3 to obtain amino acid sequences homologous to the protein
molecules of interest. Where gaps exist n two sequences, Gapped BLAST can be
utilized as described in ul et al., Nucleic Acids Res. 25(17):3389—3402, 1997. When
utilizing BLAST and Gapped BLAST programs, the default ters of the respective
programs (e.g., XBLAST and NBLAST) can be used.
In some embodiments, the cysteine mutants described herein can contain one or more
mutations (e.g., conservative amino acid substitutions) within the framework regions (FRs) as
compared to the two exemplary mutants described above and in Example 1 below. As known
in the art, mutations within the FR regions are unlikely to affect the antigen—binding activity
of the dy. In other embodiments, the cysteine s described herein can contain one
or more mutations (e.g., l, 2, or 3 ons such as conservative amino acid substitutions)
within one or more of the CDR regions as compared to 532A—X53—C02 or that of 532A—X53—
B03. Preferably, such mutants retain the same regions/residues responsible for antigen—
binding as the parent, such as the same icity—determining es inside the CDRs.
In general, a cysteine residue provides a protein with unique properties because a
ne residue can form a covalent bond with other cysteines. Mutating a cysteine often
s in proteins with significantly altered ties. It was therefore unexpected that the
antibodies with the cysteine in CDR3 of light chain mutated to either a serine (C54—C02) or
an alanine (X54—B03) were found to be more homogeneous than DX—2504, as measured by
size exclusion chromatography (Figure l) and by SDS—PAGE analysis (Figure 2). It was also
unexpected that cysteine mutants would be more stable, with respect to the percent
monomeric IgG species, over a 30 day incubation at 37°C tion (Figure 3) or following
a 15 day incubation at pH 8.3 (Figure 4). Mutations in the CDRs of an antibody often
diminish the affinity of antigen binding. It was therefore further unexpected that mutating a
cysteine in the CDR3 of the light chain of DX—2504 did not affect the affinity of antigen
binding (Figures 7 and 8).
Any of the cysteine s described above can further comprise a heavy chain
variable region (VH), which comprises VH CDRl, VH CDR2, and VH CDR3 regions. The VH
can be the same as that of DX2504 (SEQ ID NO:9) or a functional variant f. In some
embodiments, the VH CDRs in the functional variant share at least 70% (e. g., at least 75%,
80%, 85%, 90%, or 95%) sequence identity to those of DX2504 (SEQ ID NOs: 22, 23, and
24). In one example, one or more of the VH CDRs share at least 70% sequence ty to
that of the corresponding VH CDR(s) of DX2504, for example, having at least 70% homology
(at least 75%, 80%, 85%, 90%, or 95%) in the VH CDR3 region with the sequences
LAIGDSY (SEQ ID NO:24).
In another example, the VH CDRs of the functional variant, in combination, share at
least 70% sequence ty to those of , in ation. For example, an antibody
with at least 90% gy in the CDRl, CDR2 and CDR3 region with the reference CDR
sequences refers to an antibody that has at least 9 out of every 10 amino acids in the
combined CDRl, CDR2 and CDR3 regions identical to the amino acids found in the
combined CDRl, CDR2 and CDR3 regions of DX2504.
Alternatively, the functional mutant can contain up to 1, up to 2, up to 3, up to 4, or up
to 5 amino acid substitutions in the CDR3 region as compared to the CDR3 sequences of
DX2504 (LAIGDSY; SEQ ID NO:24). In some embodiments, the functional variants include
up to 3 substitutions in the VH CDR3 region as compared to the CDR3 region of DX2504. In
one example, the one or more of the amino acids substitutions are conservative amino acid
substitutions.
er, the functional variant can contain up to 1, up to 2, up to 3, up to 4, up to 5,
up to 6, up to 7, up to 8, up to 9, up to 10, up to 11, up to 12, up to 13, up to 14, or up to 15
amino acid substitutions in the CDR1, CDR2 and CDR3 region as compared to the sequences
of the CDR1, CDR2 and CDR3 regions of DX2504. In some embodiments, they contain up
to 10 substitutions in the VH CDR1, CDR2, and CDR3 regions collectively. In one example,
the one or more of the amino acids substitutions are conservative amino acid substitutions.
In some embodiments, the functional variant comprises a VH chain that share at least
70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 97%, or 98%) sequence identity to the VH
sequence of DX2504 (SEQ ID NO:9). In one e, the functional variant comprises the
same VH CDR3 region as DX2504, and ally, the same VH CDRl and CDR2 regions as
DX2504.
When desired, the functional variant of DX2504 heavy chain as described herein can
contain one or more mutations (e.g., conservative amino acid substitutions) Within the
framework regions (FRs) of DX2504 (see above description). As known in the art, ons
Within the FR regions are unlikely to affect the antigen—binding ty of the antibody. In
other embodiments, the cysteine s described herein can contain one or more mutations
(e. g., l, 2, or 3 mutations such as conservative amino acid tutions) Within one or more
of the CDR regions as compared to DX2504. Preferably, such variants retain the same
regions/residues responsible for antigen—binding as the parent, such as the same specificity—
determining residues inside the CDRs.
In one example, the cysteine mutant of DX2504 described herein comprises a light
chain at least 70% (e.g., at least 75%, 80%, 85%, 90%, or 95%) homology With 532A—X53—
C02 or 532A—X53—B03, and a heavy chain comprising the same CDRs as that of DX2504
(e. g., the same heavy chain variable region as that of DX2504). In r example, the
mutant comprises the same VL as 532A—X53—C02 or 532A—X53—B03, and the same VH as
DX2504.
Deletion Mutants
It has also been discovered, unexpectedly, that the deletion of the inal lysine
residue of the heavy chain of DX2504 resulted in an cRn antibody (DX2507) having
increased antibody retention and a higher reduction of IgG in an animal model as compared
to DX2504 (Figures 13 and 14).
Accordingly, also described herein are deletion mutants that lack the inal
lysine e in its heavy chain as compared to the heavy chain of . More
specifically, the heavy chain of the deletion mutant described herein can be otherwise
identical to the heavy chain of DX2504 (SEQ ID NO: 17) or to the heavy chain of any of the
functional ts of DX2504 as described above except for the deletion of the amino acid
residue corresponding to the C—terminal lysine residue in the heavy chain of DX2504 (SEQ
ID NO: 17). One example of such a heavy chain is that of DX2507 (SEQ ID NO: 19)
described in e 2 below.
The deletion mutants described above can further comprise a light chain, which can
comprise the VL region of DX2504 or the VL region of any of the cysteine mutants bed
herein.
In some examples, the deletion mutant comprises a light chain comprising the same
VL CDRs as DX2504, 532A—X53—C02, or 532A—X53—B03 (e.g., the same VL as DX2504,
532A—X53—C02, or 532A—X53—B03), a heavy chain comprising the same VH CDRs as
DX2504 (e.g., the same VH as DX2504) and a heavy chain constant region having a deletion
at the position corresponding to the C—terminal lysine residue of the heavy chain of DX2504.
Any of the cysteine and deletion mutants described herein can bind to human FcRn
with a dissociation constant (KD) of less than 10 nM.
In addition to having the amino acids sequences described herein, the anti—FcRn
antibodies described herein may have any structural framework. Thus, for instance the
CDRl, CDR2, ad CDR3 regions described above, may be embedded in a “traditional”
antibody framework, or may embedded in a scFv or Fab framework. The anti—FcRn antibody
described herein can be a full—length antibody or an antigen—binding fragment thereof, e.g.,
Fab, F(ab)’2, Fv or ScFv antibody. It can be a non—human antibody such as a murine
antibody (e.g., a onal antibody produced by a hybridoma cell line), a chimeric
dy, or a humanized antibody.
Also within the scope of the present disclosure are nucleic acids comprising
nucleotide sequences encoding the VH and/or VL of any of the anti—FcRn dies described
herein (e.g., any of the cysteine mutants or any of the deletion mutants described above).
Such c acid sequences can be inserted into expression vectors, which can be introduced
into suitable host cells (e.g., bacterial cells such as E. coli cells, yeast cells, insect cells, plant
cells, or mammalian cells) for production of the anti—FcRn antibodies via recombinant
technology.
Methods of Making Mouse Monoclonal Antibodies
Methods of making monoclonal antibodies have been described (Harlow et al.,
Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
(1988)). In some instances, as a first step, a rodent, 6.57., a mouse is zed with an
antigenic polypeptide to generate an antibody response. Because FcRn is expressed
ubiquitously and exhibits high degree of homology between species, polypeptide
zation has not been successful in ing high affinity FcRn ic monoclonal
antibodies or FcRn monoclonal blocking antibodies. To solve this problem DNA vaccination
can be performed (Castagliola et al., J. Immunology 160:1458 ). DNA vaccination
involves zing a rodent, e.g., a mouse with a cDNA construct encoding FcRn or a
fragment thereof. zation can be stered intramuscularly, intraperitoneally,
subcutaneously, intravenously, ermally or directly into the lymph node. In one
embodiment the immunizations stered intramuscularly. DNA vaccination can be
administered with an adjuvant, e.g. Freunds complete adjuvant or Freund’s incomplete
nt. The DNA vaccination can be accompanied by administration of a cardiotoxin to
increase the antibody titer. Administration of a cardiotoxin causes cell death and cell
regeneration which enhances cellular uptake of the administered DNA vaccine. The
toxin can also increase inflammation which results in a more robust immune response.
Antibody secreting cells (B cells) are isolated from the rodent. Typically the B cell
can be isolated from the rodents spleen and fused with a myeloma cell line. The myeloma cell
lines are immortalized cell lines that do not produce antibodies. The a cell line can
be chosen from, but is not limited to P3—X63Ag8, X63Ag8.653, Sp2/0—Agl4, FO, NSI/l-
Ag4-l, NSO/l, FOX-NY, Y3-Agl.2.3, YB2/0 and IR983F.
Splenocytes are fused with the myeloma cell line to form a hybridoma. Fusion can be
mediated by mixing the two cell types with polyethylene glycol for an appropriate period of
time (e.g. five minutes). The formed hybridomas are grown in cell culture using an
appropriate selection media (e.g. HAT) and screened for their ability to produce a
monoclonal dy against FcRn. Screening can be performed using known
immunological techniques, 6.57. an ELISA.
r approach to making FcRn specific monoclonal antibodies is to immunize a
transgenic FcRn knockout mouse with soluble human FcRn, see, PCT Application WO
02/43658. WO 02/43658 describes a transgenic mouse whose genome comprises a
homozygous disruption in its endogenous FcRn gene, wherein said homozygous disruption
prevents expression of a functional FcRn protein. The monoclonal dy of the ion
is not made in a transgenic mouse whose genome comprises a homozygous disruption in its
endogenous FcRn gene, wherein said homozygous disruption prevents expression of a
functional FcRn protein. The monoclonal antibody of the ion is not comprised of a B
cell from a transgenic mouse whose genome comprises a homozygous tion in its
endogenous FcRn gene, wherein said homozygous disruption prevents expression of a
onal FcRn protein.
Humanized Anti—FcRn Antibodies Display Libraries
A display library can be used to identify antibodies that bind to the FcRn. A display
library is a collection of entities; each entity includes an accessible polypeptide component
and a recoverable ent that encodes or fies the polypeptide component. The
polypeptide component is varied so that different amino acid sequences are represented. The
polypeptide component can be of any length, 6.57. from three amino acids to over 300 amino
acids. In a selection, the polypeptide component of each member of the library is probed
with the FcRn and if the polypeptide component binds to the FcRn, the display library
member is identified, lly by retention on a support. In addition, a display library entity
can include more than one polypeptide component, for example, the two polypeptide chains
of an sFab.
Retained display library members are recovered from the t and analyzed. The
analysis can include amplification and a subsequent selection under similar or dissimilar
conditions. For example, positive and negative selections can be ated. The analysis can
also include determining the amino acid sequence of the polypeptide component and
cation of the polypeptide component for detailed characterization.
A variety of formats can be used for display libraries. Examples include the
following.
WO 67039
Phage Display. One format utilizes viruses, particularly iophages. This format
is termed “phage display.” The protein component is typically covalently linked to a
bacteriophage coat protein. The linkage results from translation of a nucleic acid encoding
the protein component fused to the coat protein. The linkage can e a flexible e
linker, a protease site, or an amino acid incorporated as a result of suppression of a stop
codon. Phage display is described, for example, in US. 5,223,409; Smith (1985) Science
228:1315-1317; WO 92/18619; WO 91/17271; WO 92/20791; WO 92/15679; WO 88;
WO 92/01047; WO 92/09690; WO 90/02809; de Haard et al. (1999) J. Biol. Chem
274:18218—30; Hoogenboom et al. (1998) Immunotechnology 4:1—20; Hoogenboom et al.
(2000) Immunol Today 2:371—8; Fuchs et al. (1991) Bio/Technology 9:1370—1372; Hay et al.
(1992) Hum Antibod Hybridomas 3:81—85; Huse et al. (1989) Science 246:1275—1281;
Griffiths et al. (1993) EMBO J 12:725—734; Hawkins et al. (1992) JMol Biol 9—896;
Clackson et al. (1991) Nature 352:624—628; Gram et al. (1992) PNAS 6—3580; Garrard
et al. (1991) Bio/Technology 9: 1373— 1377; and boom et al. (1991) Nuc Acid Res
19:4133—4137.
Phage display systems have been developed for filamentous phage (phage f1, fd, and
M13) as well as other bacteriophage. The filamentous phage display systems typically use
fusions to a minor coat protein, such as gene III protein, and gene VIII protein, a major coat
n, but fusions to other coat proteins such as gene VI protein, gene VII protein, gene IX
protein, or domains thereof can also been used (see, e. 57., WO 00/71694). In one
embodiment, the fusion is to a domain of the gene III protein, e. g., the anchor domain or
“stump,” (see, e.g., US. Patent No. 5,658,727 for a description of the gene III protein anchor
domain). It is also possible to physically associate the protein being displayed to the coat
using a ptide linkage.
Bacteriophage displaying the n component can be grown and harvested using
standard phage preparatory methods, e. 57., PEG precipitation from growth media. After
selection of individual display , the nucleic acid encoding the selected protein
components can be isolated from cells infected with the selected phages or from the phage
themselves, after amplification. dual colonies or plaques can be picked, the nucleic
acid ed and sequenced.
Other Display Formats. Other display formats include cell based display (see, e.g.,
WO 03/029456), protein—nucleic acid fusions (see, e. 57., US 6,207,446), and ribosome display
(See, e.g., Mattheakis et al. (1994) Proc. Natl. Acad. Sci. USA 91:9022 and Hanes et al.
(2000) Nat Biotechnol. 7—92; Hanes et al. (2000) Methods Enzymol. 328:404—30; and
Schaffitzel et al. (1999) J Immunol Methods. 2): 1 19-35).
Scaffolds. lds for display can include: antibodies (e.g., Fab fragments, single
chain Fv molecules (scFV), single domain antibodies, camelid antibodies, and camelized
antibodies); T—cell receptors; MHC proteins; extracellular domains (e.g., fibronectin Type III
repeats, EGF repeats); protease inhibitors (e.g., Kunitz domains, ecotin, BPTI, and so forth);
TPR repeats; trifoil structures; zinc finger s; DNA—binding proteins; particularly
monomeric DNA binding ns; RNA binding proteins; s, e.g., proteases
(particularly inactivated proteases), RNase; chaperones, e.g., thioredoxin and heat shock
proteins; intracellular ing domains (such as SH2 and SH3 domains); linear and
constrained es; and linear peptide substrates. Display libraries can include synthetic
and/or natural diversity. See, e.g., US 2004—0005709.
Display technology can also be used to obtain antibodies that bind particular epitopes
of a . This can be done, for example, by using competing non—target molecules that
lack the particular epitope or are mutated within the epitope, e.g. with alanine. Such non—
target molecules can be used in a negative selection procedure as described below, as
competing molecules when binding a display library to the , or as a pre—elution agent,
e.g., to capture in a wash solution dissociating display library members that are not specific to
the target.
Iterative Selection. In one embodiment, display library technology is used in an
iterative mode. A first display library is used to identify one or more antibodies that bind a
target. These identified antibodies are then varied using a mutagenesis method to form a
second display library. Higher affinity antibodies are then selected from the second library,
e.g. , by using higher stringency or more competitive binding and g ions.
In some entations, the mutagenesis is targeted to regions known or likely to be
at the binding interface. In the case of antibodies, the mutagenesis can be directed to the CDR
regions of the heavy or light chains as described . Further, mutagenesis can be directed
to framework regions near or adjacent to the CDRs. In the case of antibodies, mutagenesis
can also be limited to one or a few of the CDRs, e.g., to make precise step—wise
improvements. ary nesis techniques include: error—prone PCR, recombination,
DNA shuffling, site—directed mutagenesis and cassette mutagenesis.
In one example of iterative selection, the methods described herein are used to first
identify an antibody from a display library that binds an FcRn with at least a l binding
specificity for a target or a l activity, e.g., an equilibrium dissociation nt for
binding of less than 1 nM, 10 nM, or 100 nM. The nucleic acid ce encoding the initial
identified antibodies are used as a template nucleic acid for the introduction of variations,
6.57., to fy a second antibody that has enhanced properties (e.g., binding affinity,
kinetics, or stability) relative to the initial antibody.
Off-Rate Selection. Since a slow dissociation rate can be predictive of high affinity,
particularly with respect to ctions between antibodies and their targets, the s
described herein can be used to isolate antibodies with a desired kinetic iation rate
(e.g., reduced) for a binding interaction to a target.
To select for slow dissociating antibodies from a display library, the library is
contacted to an immobilized target. The immobilized target is then washed with a first
solution that removes non—specifically or weakly bound biomolecules. Then the bound
antibodies are eluted with a second solution that includes a saturating amount of free target or
a target specific high—affinity competing monoclonal dy, i.e., replicates of the target
that are not attached to the particle. The free target binds to biomolecules that dissociate
from the target. Rebinding is effectively prevented by the saturating amount of free target
relative to the much lower tration of immobilized target.
The second solution can have solution ions that are ntially physiological
or that are stringent. Typically, the solution conditions of the second solution are identical to
the solution conditions of the first solution. Fractions of the second solution are collected in
temporal order to guish early from late fractions. Later fractions include biomolecules
that dissociate at a slower rate from the target than biomolecules in the early fractions.
Further, it is also possible to recover display library members that remain bound to the
target even after extended incubation. These can either be dissociated using chaotropic
conditions or can be amplified while attached to the target. For example, phage bound to the
target can be contacted to bacterial cells.
Selecting 0r Screening for Specificity. The display library screening methods
described herein can include a selection or screening process that discards display library
members that bind to a non—target le. es of non—target molecules include
streptavidin on magnetic beads, blocking agents such as bovine serum n, non—fat
2012/040409
bovine milk, any ing or target lizing monoclonal antibody, or non—transfected
cells which do not s the human FcRn target.
In one implementation, a so—called “negative selection” step is used to discriminate
between the target and related non—target le and a related, but distinct rget
molecules. The y library or a pool thereof is contacted to the non—target molecule.
Members of the sample that do not bind the non—target are collected and used in subsequent
selections for binding to the target molecule or even for subsequent negative selections. The
negative selection step can be prior to or after selecting library members that bind to the
target molecule.
In another implementation, a screening step is used. After display library members
are isolated for binding to the target molecule, each isolated library member is tested for its
ability to bind to a non—target molecule (e.g., a non—target listed . For example, a high—
throughput ELISA screen can be used to obtain this data. The ELISA screen can also be used
to obtain quantitative data for binding of each library member to the target as well as for
cross species reactivity to related targets or subunits of the target (e.g., rat FcRn; B2
microglobulin) and also under different condition such as pH6 or pH 7.5. The non—target and
target binding data are ed (e.g., using a computer and software) to identify library
members that specifically bind to the target.
Other Expression Libraries
Other types of collections of proteins (e.g., expression libraries) can be used to
fy proteins with a ular property (e.g., ability to bind FcRn and/or ability to
modulate FcRn), including, e.g., protein arrays of antibodies (see, e.g., De Wildt et al. (2000)
Nat. Biotechnol. 18:989—994), lambda gtll libraries, two—hybrid libraries and so forth.
Antibody Libraries
In one embodiment, the library presents a diverse pool of polypeptides, each of which
includes an immunoglobulin domain, e.g., an immunoglobulin variable domain. Display
libraries are ularly useful, for example, for identifying human or “humanized”
antibodies that recognize human antigens. Such antibodies can be used as therapeutics to treat
human disorders such as autoimmune disorders. Because the constant and framework
regions of the antibody are human, these therapeutic antibodies may avoid themselves being
recognized and targeted as antigens. The constant regions may also be optimized to recruit
effector functions of the human immune system. The in vitro display selection process
surmounts the inability of a normal human immune system to generate antibodies against
self—antigens.
A typical antibody display y ys a polypeptide that includes a VH domain
and a VL domain. An “immunoglobulin ” refers to a domain from the variable or
constant domain of immunoglobulin molecules. Immunoglobulin domains typically contain
two B—sheets formed of about seven nds, and a conserved disulphide bond (see, 6.57., A.
F. Williams and A. N. Barclay, 1988, Ann. Rev. Immunol. 6:381—405). The display library
can display the antibody as a Fab fragment (e.g., using two polypeptide chains) or a single
chain Fv (e.g., using a single ptide chain). Other formats can also be used.
As in the case of the Fab and other formats, the displayed antibody can include one or
more constant regions as part of a light and/or heavy chain. In one embodiment, each chain
includes one constant region, 6.57., as in the case of a Fab. In other embodiments, onal
constant regions are displayed.
Antibody libraries can be constructed by a number of processes (see, e.g., de Haard et
al., 1999, J. Biol. Chem. 218—30; Hoogenboom et al., 1998, Immunotechnology 4:1—20;
and Hoogenboom et al., 2000, Immunol. Today 21:371—378. Further, elements of each
process can be combined with those of other processes. The processes can be used such that
variation is uced into a single immunoglobulin domain (e.g., VH or VL) or into multiple
immunoglobulin domains (e.g., VH and VL). The variation can be introduced into an
immunoglobulin variable domain, 6.57., in the region of one or more of CDRl, CDR2, CDR3,
FRl, FR2, FR3, and FR4, ing to such regions of either and both of heavy and light
chain variable domains. In one ment, variation is introduced into all three CDRs of a
given variable domain. In another embodiment, the variation is introduced into CDRl and
CDR2, 6.57., of a heavy chain variable domain. Any combination is feasible. In one process,
antibody libraries are constructed by inserting diverse oligonucleotides that encode CDRs
into the corresponding regions of the nucleic acid. The oligonucleotides can be synthesized
using monomeric nucleotides or trinucleotides. For example, Knappik et al., 2000, J. Mol.
Biol. 296:57—86 describe a method for ucting CDR encoding ucleotides using
trinucleotide sis and a template with engineered restriction sites for accepting the
oligonucleotides.
In another process, an animal, 6.57., a rodent, is immunized with the FcRn. The animal
is optionally boosted with the antigen to further stimulate the response. Then spleen cells are
isolated from the animal, and nucleic acid encoding VH and/or VL domains is amplified and
cloned for expression in the display library.
In yet another process, antibody libraries are constructed from nucleic acid amplified
from naive germline immunoglobulin genes. The ied nucleic acid includes nucleic
acid ng the VH and/or VL domain. Sources of immunoglobulin—encoding c acids
are described below. Amplification can include PCR, 6.57., with primers that anneal to the
ved constant region, or another amplification method.
Nucleic acid encoding globulin domains can be ed from the immune
cells of, 6.57., a human, a e, mouse, , camel, llama or rodent. In one example, the
cells are selected for a particular property. B cells at various stages of maturity can be
selected. In r example, the B cells are naive.
In one embodiment, fluorescent—activated cell sorting (FACS) is used to sort B cells
that express surface—bound IgM, IgD, or IgG les. Further, B cells expressing different
isotypes of IgG can be isolated. In another ment, the B or T cell is cultured in vitro.
The cells can be stimulated in vitro, 6.57., by culturing with feeder cells or by adding mitogens
or other modulatory reagents, such as antibodies to CD40, CD40 ligand or CD20, phorbol
myristate acetate, bacterial lipopolysaccharide, concanavalin A, phytohemagglutinin, or
pokeweed mitogen.
In still one embodiment, the cells are isolated from a subject that has an autoimmune
disorder, e.g., systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, Sjogren
syndrome, systemic sclerosis, or anti—phospholipid syndrome. The subject can be a human,
or an animal, 6.57., an animal model for the human disease, or an animal having an analogous
disorder. In yet one embodiment, the cells are ed from a transgenic non—human animal
that includes a human immunoglobulin locus.
In one embodiment, the cells have activated a program of somatic hypermutation.
Cells can be stimulated to undergo somatic mutagenesis of immunoglobulin genes, for
example, by treatment with anti—immunoglobulin, anti—CD40, and D38 antibodies (see,
e.g., Bergthorsdottir et al., 2001, J. Immunol. 166:2228). In one embodiment, the cells are
naive.
The nucleic acid encoding an immunoglobulin variable domain can be isolated from a
l repertoire by the following exemplary method. First, RNA is ed from the
immune cell. Full length (i.e., capped) mRNAs are separated (e.g., by degrading uncapped
RNAs with calf intestinal phosphatase). The cap is then removed with tobacco acid
pyrophosphatase and reverse transcription is used to produce the cDNAs.
The reverse transcription of the first (antisense) strand can be done in any manner
with any suitable primer. See, e.g., de Haard et al., 1999, J. Biol. Chem. 218—30. The
primer binding region can be constant among different immunoglobulins, 6.57., in order to
reverse transcribe different isotypes of immunoglobulin. The primer binding region can also
be specific to a particular isotype of immunoglobulin. Typically, the primer is ic for a
region that is 3’ to a sequence encoding at least one CDR. In one ment, poly—dT
s may be used (and may be preferred for the heavy—chain genes).
A synthetic sequence can be ligated to the 3’ end of the reverse transcribed strand.
The synthetic sequence can be used as a primer g site for g of the forward primer
during PCR amplification after reverse transcription. The use of the synthetic ce can
obviate the need to use a pool of different forward primers to fully capture the available
diversity.
The variable —encoding gene is then amplified, 6.57., using one or more rounds.
If multiple rounds are used, nested s can be used for increased fidelity. The amplified
nucleic acid is then cloned into a display library vector.
Secondary Screening Methods
After selecting ate library members that bind to a target, each candidate library
member can be further analyzed, e.g., to further characterize its binding properties for the
target. Each candidate y member can be subjected to one or more secondary screening
assays. The assay can be for a binding property, a catalytic property, an inhibitory property, a
physiological ty (e.g., cytotoxicity, renal nce, immunogenicity), a structural
property (e.g., stability, conformation, oligomerization state) or another functional property.
The same assay can be used repeatedly, but with varying conditions, e.g., to determine pH,
ionic, or thermal sensitivities.
As appropriate, the assays can use a display library member directly, a recombinant
polypeptide produced from the nucleic acid encoding the selected polypeptide, or a synthetic
peptide synthesized based on the ce of the selected polypeptide. ary assays for
g properties include the following.
ELISA. Antibodies selected from an sion library can also be screened for a
binding property using an ELISA. For example, each antibody is ted to a microtitre
plate whose bottom surface has been coated with the target, e.g. , a limiting amount of the
target. The plate is washed with buffer to remove non—specifically bound polypeptides. Then
the amount of the antibody bound to the plate is determined by probing the plate with an
antibody that can ize the test antibody, 6.57., a tag or constant portion of the antibody.
The detection dy is linked to an enzyme such as alkaline phosphatase or horse radish
peroxidase (HRP) which produces a colorimetric product when appropriate substrates are
In the case of an antibody from a display library, the antibody can be purified from
cells or assayed in a display library format, 6.57., as a fusion to a filamentous bacteriophage
coat. In r version of the ELISA, each dy selected from an expression library is
used to coat a different well of a microtitre plate. The ELISA then proceeds using a constant
target molecule to query each well.
Homogeneous Binding Assays. The binding interaction of candidate antibody with a
target can be analyzed using a homogenous assay, i.e., after all components of the assay are
added, additional fluid manipulations are not required. For example, fluorescence resonance
energy transfer (FRET) can be used as a homogenous assay (see, for example, Lakowicz et
al., US Patent No. 5,631,169; Stavrianopoulos, et al., US Patent No. 4,868,103). A
fluorophore label on the first molecule (e.g., the molecule identified in the fraction) is
selected such that its emitted fluorescent energy can be absorbed by a fluorescent label on a
second molecule (e.g., the target) if the second molecule is in proximity to the first molecule.
The cent label on the second molecule fluoresces when it absorbs to the transferred
energy. Since the efficiency of energy er between the labels is d to the distance
separating the molecules, the spatial relationship between the molecules can be assessed. In a
situation in which binding occurs between the molecules, the fluorescent emission of the
tor’ molecule label in the assay should be maximal. A binding event that is configured
for monitoring by FRET can be conveniently measured through standard fluorometric
detection means well known in the art (e.g., using a fluorimeter). By titrating the amount of
the first or second binding molecule, a g curve can be generated to estimate the
equilibrium binding constant.
Another example of a homogenous assay is CREENTM (Packard Bioscience,
Meriden CT). ALPHASCREEN TM uses two labeled beads. One bead generates singlet
oxygen when excited by a laser. The other bead generates a light signal when singlet oxygen
diffuses from the first bead and collides with it. The signal is only generated when the two
beads are in proximity. One bead can be attached to the display library , the other to
the target. Signals are ed to determine the extent of binding.
The homogenous assays can be performed while the candidate polypeptide is attached
to the display library vehicle, 6.57., a bacteriophage.
Surface Plasmon Resonance (SPR). The binding interaction of a molecule isolated
from an expression library and a target can be analyzed using SPR. SPR or Biomolecular
Interaction Analysis (BIA) s biospecific interactions in real time, t labeling any
of the interactants. Changes in the mass at the g surface ative of a binding event)
of the BIA chip result in tions of the refractive index of light near the surface (the
optical phenomenon of e plasmon resonance (SPR)). The changes in the refractivity
generate a detectable signal, which are ed as an indication of real—time reactions
between biological molecules. Methods for using SPR are described, for example, in US.
Patent No. 5,641,640; Raether, 1988, Surface Plasmons Springer Verlag; Sjolander and
Urbaniczky, 1991, Anal. Chem. 63:2338—2345; Szabo et al., 1995, Curr. Opin. Struct. Biol.
:699—705 and on—line resources provide by e International AB (Uppsala, Sweden).
Information from SPR can be used to provide an accurate and quantitative measure of
the equilibrium dissociation constant (Kd), and kinetic ters, including K011 and Koff, for
the binding of a biomolecule to a target. Such data can be used to compare different
biomolecules. For example, selected proteins from an expression library can be compared to
identify proteins that have high affinity for the target or that have a slow Koff. This
information can also be used to develop structure—activity relationships (SAR). For example,
the kinetic and brium binding parameters of matured versions of a parent n can be
compared to the parameters of the parent protein. t amino acids at given positions can
be identified that correlate with particular binding parameters, e.g. and slow
, high affinity
Koff. This information can be combined with structural modeling (e.g., using homology
modeling, energy minimization, or structure determination by x—ray crystallography or
WO 67039
NMR). As a , an understanding of the physical interaction between the protein and its
target can be formulated and used to guide other design processes.
Cellular Assays. A library of candidate dies (e.g., preViously identified by a
display library or otherwise) can be screened for target g on cells which transiently or
stably express and display the target of interest on the cell surface. For example, the target
can e vector c acid sequences that include segments that encode only the
extracellular portion of the polypeptides such that the ic target polypeptides are
produced within the cell, secreted from the cell, or attached to the cell surface through the
anchor 6.57., in fusion with a membrane anchoring proteins such as PC. The cell surface
expressed target can be used for ing dies that bind to FcRn and block the g
of IgG—Fc. For example, non—specific human IgG—Fc could be fluorescently labeled and its
binding to FcRn in the presence of absence of antagonistic antibody can be detected by a
change in fluorescence intensity using flow cytometry 6.57., a FACS machine.
Other Methods for Obtaining FcRn—binding antibodies
In addition to the use of display libraries, other methods can be used to obtain a FcRn—
binding antibody. For example, the FcRn protein or a region thereof can be used as an
antigen in a non—human animal, e. g., a rodent.
In one embodiment, the non—human animal includes at least a part of a human
immunoglobulin gene. For example, it is possible to engineer mouse strains deficient in
mouse dy production with large fragments of the human Ig loci. Using the hybridoma
technology, antigen—specific monoclonal antibodies (Mabs) derived from the genes with the
desired specificity may be ed and selected. See, e.g., XENOMOUSETM, Green et al.,
1994, Nat. Gen. 7:13—21; U.S. 2003—0070185, WO 96/34096, published Oct. 31, 1996, and
PCT Application No. PCT/US96/05928, filed Apr. 29, 1996.
In one embodiment, a monoclonal antibody is obtained from the non—human animal,
and then modified, e.g., humanized or deimmunized. Winter describes a CDR—grafting
method that may be used to prepare the humanized antibodies (UK Patent Application GB
2188638A, filed on March 26, 1987; US Patent No. 5,225,539. All of the CDRs of a
particular human antibody may be replaced with at least a portion of a man CDR or
only some of the CDRs may be replaced with non—human CDRs. It is only necessary to
replace the number of CDRs required for binding of the humanized antibody to a
ermined antigen.
2012/040409
Humanized antibodies can be generated by replacing ces of the Fv variable
region that are not directly involved in antigen binding with equivalent sequences from
human Fv variable regions. General methods for generating humanized antibodies are
provided by Morrison, S. L., 1985, Science 229:1202—1207, by Oi et al., 1986, BioTechniques
4:214, and by Queen et al. US Patent Nos. 5,585,089, US 5,693,761 and US 5,693,762.
Those methods include isolating, manipulating, and expressing the nucleic acid sequences
that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or
light chain. Sources of such nucleic acid are well known to those skilled in the art and, for
example, may be obtained from a hybridoma producing an antibody against a predetermined
target, as bed above. The recombinant DNA encoding the humanized antibody, or
fragment thereof, can then be cloned into an appropriate sion vector.
An FcRn—binding antibody may also be ed by specific deletion of human T cell
epitopes or unization" by the methods disclosed in WO 98/52976 and WO 00/34317,
the contents of which are specifically incorporated by reference herein. Briefly, the heavy
and light chain le regions of an dy can be analyzed for peptides that bind to MHC
Class 11; these peptides represent potential T—cell es (as defined in WO 98/52976 and
WO 00/34317). For detection of potential T—cell epitopes, a computer modeling approach
termed “peptide threading” can be applied, and in addition a database of human MHC class II
g peptides can be searched for motifs present in the VH and VL sequences, as described
in WO 98/52976 and WO 00/34317. These motifs bind to any of the 18 major MHC class 11
DR allotypes, and thus tute potential T cell epitopes. ial T—cell epitopes detected
can be ated by substituting small numbers of amino acid residues in the variable
s or by single amino acid substitutions. As far as possible conservative substitutions
are made, often but not exclusively, an amino acid common at this position in human
germline antibody sequences may be used. Human germline sequences are disclosed in
Tomlinson, I.A. et al., 1992, J. Mol. Biol. 227:776—798; Cook, G. P. et al., 1995, Immunol.
Today Vol. 16 (5): 237-242; Chothia, D. et al., 1992, J. Mol. Bio. 9-817. The V BASE
directory provides a comprehensive directory of human immunoglobulin variable region
sequences (compiled by Tomlinson, I.A. et al. MRC Centre for Protein ering,
Cambridge, UK). After the deimmunizing changes are identified, nucleic acids encoding VH
and VL can be constructed by mutagenesis or other synthetic methods (e.g., de novo
synthesis, cassette ement, and so forth). Mutagenized variable sequence can,
optionally, be fused to a human constant region, e.g., human IgGl or K constant regions.
In some cases, a ial T cell epitope will include es which are known or
predicted to be important for antibody function. For example, potential T cell es are
usually biased towards the CDRs. In addition, potential T cell epitopes can occur in
framework residues important for antibody structure and binding. Changes to eliminate these
potential epitopes will in some cases require more scrutiny, 6.57., by making and g chains
with and without the change. Where possible, potential T cell epitopes that overlap the CDRs
were eliminated by substitutions outside the CDRs. In some cases, an alteration within a
CDR is the only option, and thus variants with and without this substitution should be tested.
In other cases, the substitution required to remove a potential T cell epitope is at a residue
position within the framework that might be critical for antibody binding. In these cases,
variants with and without this substitution should be tested. Thus, in some cases several
variant deimmunized heavy and light chain variable regions were designed and various
heavy/light chain ations tested in order to identify the optimal deimmunized antibody.
The choice of the final deimmunized antibody can then be made by ering the binding
affinity of the different ts in conjunction with the extent of deimmunization, i.e., the
number of potential T cell epitopes remaining in the variable region. Deimmunization can be
used to modify any antibody, 6.57., an antibody that es a non—human sequence, 6.57., a
synthetic dy, a murine antibody other non—human monoclonal antibody, or an antibody
isolated from a display library.
Germlining Antibodies.
An antibody used to treat an IgG—mediated autoimmune disease can be used for
multiple administrations. tions that would lower the immunogenicity of the
therapeutic antibody include reverting one or more non—germline amino acids in framework
regions to corresponding germline amino acids (e.g., so long as binding properties are
ntially retained) of the antibody (especially of Fabs).
It is possible to modify an antibody that binds FcRn, 6.57., an antibody described
herein, in order to make the variable regions of the antibody more similar to one or more
germline ces. For example, an antibody can include one, two, three, or more amino
acid substitutions, 6.57., in a framework, CDR, or constant , to make it more similar to a
reference germline sequence. One ary germlining method can include identifying one
or more germline sequences that are r (e.g., most r in a particular database) to the
ce of the isolated antibody. Mutations (at the amino acid level) can then be made in
the isolated antibody, either incrementally or in combination with other mutations. For
example, a nucleic acid library that includes sequences encoding some or all le
germline mutations is made. The mutated antibodies are then evaluated, e.g., to identify an
antibody that has one or more additional germline residues relative to the isolated antibody
and that is still useful (e.g., has a functional activity). In one embodiment, as many germline
residues are introduced into an isolated antibody as possible.
In one embodiment, mutagenesis is used to substitute or insert one or more germline
residues into a framework and/or constant region. For example, a germline ork and/or
constant region residue can be from a ne sequence that is similar (e.g., most similar) to
the non—variable region being modified. After mutagenesis, activity (e.g., binding or other
functional activity) of the antibody can be evaluated to determine if the germline residue or
residues are tolerated (i.e., do not abrogate activity). Similar mutagenesis can be performed
in the framework s.
Selecting a germline sequence can be performed in different ways. For example, a
germline sequence can be selected if it meets a ermined ia for selectivity or
similarity, 6.57., at least a certain percentage identity, 6.57., at least 75, 80, 85, 90, 91, 92, 93,
94, 95, 96, 97, 98, 99, or 99.5% ty. The selection can be performed using at least 2, 3,
, or 10 ne sequences. In the case of CDRl and CDR2, identifying a similar germline
ce can include selecting one such sequence. In the case of CDR3, identifying a similar
germline sequence can include selecting one such sequence, but may including using two
germline sequences that separately contribute to the terminal portion and the carboxy—
terminal portion. In other entations more than one or two germline sequences are
used, 6.57., to form a consensus sequence.
In one ment, with respect to a particular reference variable domain sequence,
6.57., a sequence described herein, a related variable domain sequence has at least 30, 40, 50,
60, 70, 80, 90, 95 or 100% of the CDR amino acid positions that are not identical to residues
in the reference CDR sequences, residues that are identical to residues at corresponding
positions in a human germline sequence (i.e., an amino acid sequence encoded by a human
germline nucleic acid).
W0 2012/167039
In one embodiment, with respect to a particular reference variable domain sequence,
6.57., a sequence described herein, a related variable domain sequence has at least 30, 50, 60,
70, 80, 90 or 100% of the FR regions are identical to FR sequence from a human germline
sequence, 6.57., a germline sequence related to the reference variable domain sequence.
Accordingly, it is possible to isolate an antibody which has r activity to a given
dy of interest, but is more similar to one or more germline sequences, particularly one
or more human germline ces. For example, an antibody can be at least 90, 91, 92, 93,
94, 95, 96, 97, 98, 99, or 99.5% identical to a germline sequence in a region outside the
CDRs (e.g., framework regions). Further, an antibody can include at least 1, 2, 3, 4, or 5
germline residues in a CDR region, the germline residue being from a germline sequence of
similar (e.g., most similar) to the variable region being ed. Germline sequences of
primary st are human germline sequences. The activity of the antibody (e.g., the
binding activity) can be Within a factor or 100, 10, 5, 2, 0.5, 0.1, and 0.001 of the original
antibody.
Exemplary germline reference ces for Vkappa include: , 018/08, A20,
A30, L14, L1, L15, L4/18a, L5/L19, L8, L23, L9 ,L24, L11, L12, 011/01, A17, A1, A18,
A2, A19/A3, A23, A27, A11, , L6, L20, L25, B3, B2, 0, and A14. See, e.g.,
Tomlinson et al., 1995, EMBO J. :4628—3.
A germline reference sequence for the HC variable domain can be based on a
sequence that has particular canonical structures, 6.57., 1—3 structures in the H1 and H2
hypervariable loops. The canonical structures of hypervariable loops of an immunoglobulin
variable domain can be inferred from its sequence, as described in Chothia et al., 1992, J.
M01. Biol. 227:799—817; Tomlinson et al., 1992, J. M01. Biol. 227:776—798); and son
et al., 1995, EMBO J. 14(18):4628—38. Exemplary sequences with a 1—3 structure include:
DP-l, DP-8, DP-12, DP-2, DP-25, DP-15, DP-7, DP-4, DP-31, DP-32, DP-33, DP-35, DP-
40, 7—2, hv3005, hv3005f3, DP-46, DP-47, DP-58, DP-49, DP-50, DP-51, DP-53, and DP-54.
Ligand Production
Standard recombinant nucleic acid methods can be used to express an antibody that
binds to FcRn. Generally, a nucleic acid sequence encoding the dy is cloned into a
nucleic acid expression vector. Of course, if the dy includes multiple polypeptide
, each chain can be cloned into an expression vector, 6.57., the same or different vectors,
that are expressed in the same or different cells.
Antibody Production. Some antibodies, e.g., Fabs, can be produced in bacterial
cells, 6.57., E. coli cells. For example, if the Fab is encoded by sequences in a phage display
vector that includes a suppressible stop codon between the y entity and a bacteriophage
protein (or nt thereof), the vector nucleic acid can be transferred into a bacterial cell
that cannot ss a stop codon. In this case, the Fab is not fused to the gene III protein
and is secreted into the periplasm and/or media.
Antibodies can also be produced in eukaryotic cells. In one embodiment, the
dies (e.g., scFv’s) are sed in a yeast cell such as Pichia (see, e.g., Powers et al.,
2001, J. Immunol. Methods. 3—35), Hanseula, or Saccharomyces.
In one embodiment, antibodies are produced in mammalian cells. Mammalian host
cells for expressing the clone antibodies or antigen—binding fragments thereof include
Chinese Hamster Ovary (CHO cells) (including dhfr— CHO cells, described in Urlaub and
Chasin, 1980, Proc. Natl. Acad. Sci. USA 77:4216—4220, used with a DHFR selectable
marker, 6.57., as described in Kaufman and Sharp, 1982, M01. Biol. 159:601 621), lymphocytic
cell lines, e.g., NSO myeloma cells and SP2 cells, COS cells, and a cell from a transgenic
animal, 6.57., a transgenic mammal. For e, the cell is a mammary epithelial cell.
In on to the nucleic acid sequence encoding the diversified immunoglobulin
domain, the inant expression vectors may carry additional sequences, such as
sequences that regulate replication of the vector in host cells (e.g., origins of replication) and
selectable marker genes. The selectable marker gene facilitates selection of host cells into
which the vector has been introduced (see 6.57., US. Patent Nos. 4,399,216, 4,634,665 and
,179,017). For example, typically the selectable marker gene confers resistance to drugs,
such as G418, hygromycin or methotrexate, on a host cell into which the vector has been
introduced. able marker genes include the dihydrofolate reductase (DHFR) gene (for
use in dhfr' host cells with methotrexate selection/amplification) and the neo gene (for G418
selection).
In an exemplary system for recombinant expression of an antibody, or antigen—
binding portion thereof, a recombinant sion vector encoding both the dy heavy
chain and the antibody light chain is introduced into dhfr' CHO cells by calcium phosphate—
mediated transfection. Within the recombinant expression vector, the antibody heavy and
light chain genes are each ively linked to enhancer/promoter regulatory elements (e.g.,
derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/AdMLP
promoter regulatory element or an SV40 enhancer/AdMLP er regulatory element) to
drive high levels of transcription of the genes. The inant expression vector also
carries a DHFR gene, which allows for selection of CHO cells that have been transfected
with the vector using methotrexate selection/amplification. The selected transformant host
cells are cultured to allow for expression of the antibody heavy and light chains and intact
antibody is recovered from the culture . Standard molecular biology techniques are
used to prepare the recombinant expression vector, transfect the host cells, select for
transformants, culture the host cells and r the antibody from the culture medium. For
example, some antibodies can be isolated by affinity chromatography with a Protein A or
Protein G coupled matrix.
For antibodies that include an Fc domain, the antibody production system may
produce antibodies in which the Fc region is glycosylated. For e, the Fc domain of
IgG molecules is ylated at asparagine 297 in the CH2 domain. This asparagine is the
site for modification with biantennary—type oligosaccharides. It has been trated that
this glycosylation is ed for effector functions mediated by ch receptors and
complement Clq (Burton and Woof, 1992, Adv. Immunol. 51:1—84; Jefferis et al., 1998,
Immunol. Rev. 163:59—76). In one embodiment, the Fc domain is produced in a ian
expression system that appropriately glycosylates the residue ponding to asparagine
297. The PC domain can also include other eukaryotic post—translational modifications.
Antibodies can also be produced by a transgenic animal. For example, US. Patent
No. 5,849,992 describes a method of expressing an antibody in the mammary gland of a
enic mammal. A transgene is constructed that includes a milk—specific promoter and
nucleic acids encoding the antibody of interest and a signal sequence for secretion. The milk
produced by females of such transgenic mammals includes, secreted—therein, the antibody of
interest. The antibody can be purified from the milk, or for some applications, used directly.
One method for producing a transgenic mouse is as follows. Briefly, a targeting
construct that encodes the antibody is njected into the male pronucleus of fertilized
oocytes. The oocytes are injected into the uterus of a pseudopregnant foster mother for the
development into viable pups. Some offspring incorporate the transgene.
Assay Systems for FcRn Candidate Antibodies
FcRn candidate antibodies can be further characterized in assays that measure their
modulatory activity toward FcRn or fragments thereof in vitro or in viva. For example, FcRn
can be combined with a substrate such as non—specific IgG or Fc portion of the IgG or
albumin under assay conditions permitting reaction of the FcRn with the ate. The assay
is performed in the absence of the FcRn candidate antibody, and in the presence of increasing
concentrations of the FcRn candidate antibody. The concentration of candidate antibody at
which 50% of the FcRn activity (e.g., binding to the substrate) is ted by the candidate
antibody is the IC50 value (Inhibitory Concentration 50%) or EC50 tive Concentration
50%) value for that antibody. Within a series or group of ate antibodies, those having
lower IC50 or EC50 values are considered more potent inhibitors of FcRn than those
dies having higher IC50 or EC50 values. In some embodiments, antibodies have an IC50
value of 800 nM, 400 nM, 100 nM, 25 nM, 5 nM, 1 nM, or less as ed in an in vitro
assay for inhibition of FcRn activity.
The candidate antibodies can also be ted for selectivity toward FcRn. For
example, a FcRn candidate antibody can be assayed for its potency toward FcRn and a panel
of cell surface receptors, such as receptors that also utilize the BZM domain, and an IC50
value or EC50 value can be determined for each receptor protein. In one ment, a
compound that demonstrates a low IC50 value or EC50 value for the FcRn, and a higher IC50
value or EC50 value for other receptors within the test panel (6. g., MHC class I molecules) is
considered to be selective toward FcRn.
Ex vivo endothelial cells or epithelial cells expressing the endogenous FcRn could be
used to follow the tosis or transcytosis of the candidate antibodies under different pH
and temperature conditions. IgG transcytosis or recycling by FcRn can be measured by
ing a labeled antibody in the presence or absence of various chemicals and under
different conditions that are known to influence or affect the intracellular trafficking pathway.
A pharmacokinetics study in rat, mice, or monkey could be performed with pH
dependent and independent FcRn binding antibodies for ining their half—life in the
serum. Likewise, the protective effect of the antibody can be assessed in viva for potential
use in immunomodulating therapy or as an salvage immunotherapy by ing the antibody
in the presence or absence of a labeled IgG or the labeled Fc portion of the IgG. A decrease
in the half—life of the d IgG/Fc in the presence of the ate antibody is an indication
of the therapeutic efficacy of the antibody.
Pharmaceutical Compositions
In another aspect, the disclosure provides compositions, e.g., pharmaceutically
acceptable itions or pharmaceutical compositions, which e an FcRn—binding
antibody. The FcRn—binding antibody can be formulated together with a pharmaceutically
acceptable carrier. Pharmaceutical compositions include eutic compositions and
diagnostic compositions, e.g., compositions that include labeled FcRn—binding dies for
in viva imaging.
A pharmaceutically acceptable carrier includes any and all solvents, sion media,
coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the
like that are physiologically compatible. Preferably, the carrier is suitable for intravenous,
intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., by
injection or infusion). Depending on the route of stration, the FcRn—binding antibody
may be coated in a al to protect the compound from the action of acids and other
natural conditions that may vate the compound.
A pharmaceutically acceptable salt is a salt that s the desired biological activity
of the parent compound and does not impart any undesired toxicological effects (see e.g.,
Berge, S.M., et al., 1977, J. Pharm. Sci. 66:1—19). Examples of such salts e acid
addition salts and base on salts. Acid addition salts include those derived from nontoxic
inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic,
phosphorous, and the like, as well as from nontoxic organic acids such as aliphatic mono— and
dicarboxylic acids, phenyl—substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids,
aliphatic and aromatic sulfonic acids, and the like. Base addition salts e those derived
from alkaline earth metals, such as sodium, potassium, magnesium, calcium, and the like, as
well as from nontoxic organic amines, such as N,N'—dibenzylethylenediamine, N—
methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and
the like.
The compositions may be in a variety of forms. These include, for example, liquid,
semi—solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible
solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
The form can depend on the intended mode of administration and therapeutic application.
Many itions are in the form of injectable or infusible solutions, such as compositions
similar to those used for administration of humans with antibodies. An exemplary mode of
administration is parenteral (e.g., intravenous, aneous, intraperitoneal, intramuscular).
In one embodiment, the FcRn—binding antibody is administered by intravenous infusion or
injection. In another embodiment, the inding dy is administered by
uscular or subcutaneous injection.
The ition can be formulated as a solution, microemulsion, dispersion,
me, or other ordered structure suitable to high drug concentration. e injectable
solutions can be prepared by incorporating the active compound (i.e., the ) in the
required amount in an appropriate solvent with one or a combination of ingredients
ated above, as required, followed by filtered sterilization. Generally, dispersions are
prepared by incorporating the active compound into a sterile vehicle that contains a basic
dispersion medium and the required other ingredients from those enumerated above. In the
case of e powders for the preparation of sterile injectable solutions, the methods of
preparation are vacuum drying and freeze—drying that yields a powder of the active ingredient
plus any additional desired ingredient from a previously sterile—filtered on thereof. The
proper fluidity of a solution can be maintained, for example, by the use of a coating such as
lecithin, by the maintenance of the required particle size in the case of dispersion and by the
use of surfactants. Prolonged absorption of injectable compositions can be brought about by
including in the composition an agent that delays absorption, for example, earate salts
and gelatin.
An FcRn—binding antibody can be administered by a variety of methods known in the
art, although for many applications, the route/mode of administration is intravenous injection
or infusion. For example, for therapeutic applications, the FcRn—binding dy can be
administered by intravenous infusion at a rate of less than 30, 20, 10, 5, or 1 mg/min to reach
a dose of about 1 to 100 mg/m2 or 7 to 25 mg/m2. The route and/or mode of administration
will vary depending upon the desired results. In certain embodiments, the active compound
may be ed with a carrier that will protect the compound against rapid release, such as a
controlled release formulation, including implants, and microencapsulated delivery systems.
Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate,
polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many
methods for the preparation of such formulations are patented or generally known. See, e.g.,
Sustained and Controlled Release Drug ry Systems, J .R. Robinson, ed., 1978, Marcel
, Inc., New York.
In certain embodiments, the antibody may be orally administered, for example, with
an inert diluent or an lable edible carrier. The compound (and other ingredients, if
d) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets,
or incorporated directly into the subject's diet. For oral therapeutic administration, the
compounds may be incorporated with excipients and used in the form of ingestible tablets,
buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. To
administer a compound disclosed herein by other than parenteral administration, it may be
ary to coat the compound with, or co—administer the nd with, a material to
t its inactivation.
Pharmaceutical compositions can be administered with medical devices known in the
art. For example, in one embodiment, a pharmaceutical composition disclosed herein can be
administered with a device, e.g., a needleless hypodermic injection , a pump, or
implant.
In certain ments, an FcRn—binding antibody can be formulated to ensure
proper distribution in viva. For e, the blood—brain barrier (BBB) excludes many
highly hilic compounds. To ensure that the therapeutic compounds disclosed herein
cross the BBB (if desired), they can be formulated, for example, in liposomes. For s
of manufacturing mes, see, e.g., US. Patent Nos. 4,522,811; 5,374,548; and 5,399,331.
The liposomes may comprise one or more moieties that are selectively orted into
specific cells or organs, thus enhance targeted drug delivery (see, e.g., V.V. Ranade, 1989, J.
Clin. Pharmacol. 29:685).
Dosage regimens are adjusted to provide the optimum desired se (e.g., a
therapeutic response). For example, a single bolus may be administered, several divided
doses may be administered over time or the dose may be proportionally reduced or increased
as indicated by the exigencies of the therapeutic situation. It is especially advantageous to
formulate parenteral compositions in dosage unit form for ease of administration and
uniformity of dosage. Dosage unit form as used herein refers to physically discrete units
suited as unitary dosages for the subjects to be treated; each unit contains a predetermined
quantity of active compound calculated to produce the desired therapeutic effect in
ation with the required pharmaceutical carrier. The specification for the dosage unit
forms can be dictated by and directly dependent on (a) the unique characteristics of the active
compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent
in the art of compounding such an active compound for the treatment of sensitivity in
individuals.
An exemplary, non—limiting range for a therapeutically or prophylactically effective
amount of an antibody disclosed herein is 0.1—20 mg/kg, or 1—10 mg/kg. An anti—FcRn
antibody can be administered, e.g., by intravenous infusion, e.g., at a rate of less than 30, 20,
, 5, or 1 mg/min to reach a dose of about 1 to 100 mg/m2 or about 5 to 30 mg/m2. Dosage
values may vary with the type and severity of the condition to be alleviated. For a particular
subject, specific dosage regimens can be adjusted over time according to the individual need
and the sional judgment of the person administering or supervising the administration
of the compositions.
The pharmaceutical compositions disclosed herein may include a therapeutically
effective amount or a prophylactically effective amount of an FcRn—binding dy
disclosed herein. A “therapeutically effective amount” refers to an amount effective, at
dosages and for periods of time necessary, to e the d therapeutic result. A
therapeutically effective amount of the composition may vary according to factors such as the
e state, age, sex, and weight of the dual, and the ability of the antibody to elicit a
desired response in the individual. A therapeutically effective amount is also one in which
any toxic or detrimental effects of the composition is outweighed by the therapeutically
beneficial effects.
Stabilization and Retention
In one embodiment, an FcRn—binding antibody is physically ated with a moiety
that improves its stabilization and/or retention in circulation, e.g., in blood, serum, lymph, or
other tissues, e.g., by at least 1.5, 2, 5, 10, or 50 fold. For example, an FcRn—binding
antibody can be associated with a polymer, e.g., a substantially non—antigenic polymers, such
as polyalkylene oxides or polyethylene oxides. le rs will vary substantially by
weight. Polymers having molecular number average weights ranging from about 200 to
about 35,000 (or about 1,000 to about 15,000, and 2,000 to about 12,500) can be used. For
e, an FcRn—binding dy can be conjugated to a water soluble polymer, e.g.,
WO 67039
hydrophilic polyvinyl polymers, e.g. polyvinylalcohol and polyvinylpyrrolidone. A non—
limiting list of such polymers include polyalkylene oxide homopolymers such as
polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols,
copolymers thereof and block copolymers thereof, provided that the water solubility of the
block copolymers is ined.
An FcRn—binding antibody described herein can be provided in a kit, e.g., as a
component of a kit. For example, the kit es (a) an FcRn—binding antibody, e.g., a
composition that includes an FcRn—binding antibody, and, optionally (b) informational
material. The informational material can be descriptive, instructional, marketing or other
material that s to the methods described herein and/or the use of an FcRn—binding
dy for the methods described .
The informational material of the kits is not limited in its form. In one embodiment,
the informational material can e information about production of the nd,
molecular weight of the compound, concentration, date of expiration, batch or production site
information, and so forth. In one embodiment, the informational material relates to using the
antibody to treat, t, or diagnosis a disorder described herein, e.g., an autoimmune
disorder.
In one embodiment, the informational material can include instructions to administer
an FcRn—binding antibody in a le manner to m the methods bed herein, e.g.,
in a suitable dose, dosage form, or mode of administration (e.g., a dose, dosage form, or
mode of administration described herein). In one embodiment, the informational material can
include instructions to administer an FcRn—binding antibody to a suitable subject, e.g., a
human, e.g., a human having, or at risk for, an autoimmune disorder (e.g., rheumatoid
arthritis or systemic lupus matosis). For example, the material can include instructions
to administer an FcRn—binding antibody to a patient with lupus or a patient with another
autoimmune disorder.
The informational material of the kits is not limited in its form. In many cases, the
ational material, e.g. is provided in printed matter, e.g., a printed text,
, instructions,
drawing, and/or photograph, e.g., a label or printed sheet. However, the informational
material can also be provided in other formats, such as computer le material, video
WO 67039
recording, or audio recording. In one embodiment, the ational material of the kit is
contact information, 6.57., a physical address, email s, website, or telephone number,
Where a user of the kit can obtain substantive information about an FcRn—binding antibody
and/or its use in the s described . Of course, the informational material can also
be provided in any combination of s.
In addition to an FcRn—binding antibody, the composition of the kit can include other
ingredients, such as a t or buffer, a stabilizer, a preservative, a flavoring agent (e.g., a
bitter antagonist or a sweetener), a fragrance or other ic ingredient, and/or a second
agent for ng an mune disorder described herein, e.g. , rheumatoid arthritis or
systemic lupus erythematosis. Alternatively, the other ients can be included in the kit,
but in different compositions or containers than an FcRn—binding antibody. In such
embodiments, the kit can include instructions for admixing an FcRn—binding dy and the
other ingredients, or for using an FcRn—binding antibody together with the other ingredients.
An FcRn—binding antibody can be provided in any form, e.g., liquid, dried or
lyophilized form. It is preferred that an FcRn—binding antibody be substantially pure and/or
sterile. When an FcRn—binding antibody is provided in a liquid solution, the liquid solution
preferably is an aqueous solution, with a sterile aqueous solution being preferred. When an
FcRn—binding antibody is provided as a dried form, reconstitution generally is by the addition
of a suitable solvent. The solvent, e.g., sterile water or buffer, can optionally be provided in
the kit.
The kit can include one or more containers for the composition containing an FcRn—
binding antibody. In some embodiments, the kit contains separate ners, dividers or
compartments for the composition and informational material. For example, the composition
can be contained in a bottle, vial, or syringe, and the informational material can be contained
in a plastic sleeve or packet. In other embodiments, the separate elements of the kit are
contained Within a single, undivided container. For example, the composition is contained in
a bottle, vial or syringe that has attached thereto the informational al in the form of a
label. In some embodiments, the kit includes a plurality (e.g., a pack) of individual
containers, each ning one or more unit dosage forms (e.g., a dosage form described
herein) of an FcRn—binding antibody. For example, the kit es a plurality of syringes,
ampules, foil packets, or blister packs, each containing a single unit dose of an FcRn—binding
dy. The ners of the kits can be air tight, waterproof (e.g., impermeable to
changes in moisture or evaporation), and/or light—tight.
The kit optionally includes a device suitable for administration of the composition,
e.g., a syringe, inhalant, pipette, forceps, measured spoon, dropper (e.g., eye dropper), swab
(e.g., a cotton swab or wooden swab), or any such delivery device. In one embodiment, the
device is an implantable device that dispenses metered doses of the antibody. The disclosure
also features a method of providing a kit, e.g., by ing components described .
Treatments
Antibodies that bind to FcRn and identified by the method described herein and/or
detailed herein have therapeutic and prophylactic utilities. These dies can be
administered to a subject to treat, prevent, and/or diagnose a variety of disorders, including
autoimmune disorders, or even to cells in culture, e.g., in vitro or ex vivo.
The term “treating” refers to administering a therapy in an amount, manner, and/or
mode effective to improve a condition, m, or parameter associated with a disorder or
to prevent progression of a disorder, to either a statistically significant degree or to a degree
detectable to one skilled in the art. An effective amount, manner, or mode can vary
depending on the subject and may be tailored to the subject. The subject can be a human or a
non—human animal, e.g., a man mammal.
The FcRn—binding antibody can be administered in a therapeutically effective amount,
e.g., such that upon single or multiple dose administration to a t, the subject exhibits an
amelioration of symptoms of a disorder, e.g., an mune disorder (e.g., toid
tis or systemic lupus erythematosis) or of a parameter indicative of ce or risk for
the disorder.
Exemplary disorders which affect many organs or localized organs in the body
include: Multiple Sclerosis, rheumatoid arthritis, inflammatory bowel diseases (IBD), lupus,
and ankylosing spondylitis. Some of these disorders are discussed below. In one aspect, the
invention provides s for the treatment of cancer. Still other disorders that can be
treated using an FcRn—binding dy include: scleroderma, Sjogren’s syndrome,
Goodpasture’s syndrome, Wegener’s granulomatosis, polymyalgia rheumatica, temporal
arteritis /gian cell arteritis, ia areata, anklosing spondylitis, antiphospholipid syndrome,
autoimmune Addison’s disease, mune hemolytic anemia, autoimmune hepatitis,
autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (ALPS),
autoimmune thrombocytopenic purpura (ATP), Behcet’s disease, bullous pemphigoid,
cardiomyopathy, celiac sprue—dermatitis, chronic fatigue syndrome immune deficiency
syndrome (CFIDS), chronic inflammatory demyelinating uropathy, cicatricial
pemphigoid, cold agglutinin disease, CREST Syndrome, Crohn’s e, Dego’s disease,
dermatomyositis, juvenile dermatomyositis, discoid lupus, essential mixed cryoglobulinemia,
fibromyalgia, fibromyositis, Grave’s disease, in—Barre syndrome, Hashimoto’s
thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA
nephropathy, insulin dependent diabetes (Type I), le arthritis, Meniere’s disease, mixed
connective tissue disease, myasthenia gravis, gus vulgaris, pemphigus foliaceus,
paraneoplastic pemphigus, pernicious anemia, polyarteritis nodosa, polychondritis,
ancular syndromes , polymyalgia rheumatica, polymyositis, dermatomyositis, primary
agammaglobulinemia, y biliary cirrhosis, psoriasis, Raynaud’s phenomenon, Reiter’s
syndrome, rheumatic fever, sarcoidosis, stiff—man syndrome, Takayasu arteritis, tive
colitis, uveitis, vasculitis, vitiligo.
In some embodiments, the anti—FcRn binding antibody is administered to remove an
unwanted eutic antibody from the bloodstream.
In some embodiments, the anti—FcRn binding antibody is administered to suppress the
level of anti—HLA antibodies. In some embodiments the level of anti—HLA antibodies is
suppressed in connection with organ lant.
Methods of administering inding antibodies are described in “Pharmaceutical
Compositions.” Suitable dosages of the molecules used will depend on the age and weight of
the subject and the particular drug used. The antibodies can be used as competitive agents to
inhibit or reduce an undesirable interaction, 6.57., between a natural or ogical agent and
the FcRn.
The FcRn g antibody can be used to deliver macro and micromolecules, 6.57., a
gene into the cell for gene therapy purposes into the endothelium or lium and target
only those tissues expressing the FcRn. The antibodies may be used to deliver a variety of
cytotoxic drugs including eutic drugs, a compound emitting radiation, molecules of
plants, fungal, or bacterial origin, biological proteins, and mixtures thereof. The cytotoxic
drugs can be intracellularly acting cytotoxic drugs, such as short range radiation emitters,
ing, for e, short range, high energy tters, as described herein.
In the case of polypeptide toxins, recombinant nucleic acid ques can be used to
construct a c acid that encodes the antibody and the cytotoxin (or a polypeptide
component thereof) as translational fusions. The recombinant nucleic acid is then expressed,
e. g., in cells and the encoded fusion polypeptide isolated.
Alternatively, the FcRn—binding antibody can be coupled to high energy radiation
_ . . 131
emitters, for example, a radioisotope, such as I, a y—emitter, which, when localized at a site,
results in a killing of several cell diameters. See, e. 57., SE. Order, “Analysis, Results, and
Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy”,
Monoclonal dies for Cancer ion and Therapy, R.W. Baldwin et al. (eds.), pp
303 316 (Academic Press 1985). Other suitable sotopes include a emitters, such as
212Bi, 213Bi, and 211At, and b emitters, such as 186Re and 90Y. W
Moreover, Lu may also be
used as both an imaging and cytotoxic agent.
Radioimmunotherapy (RIT) using antibodies labeled with 131I ,90Y, and 177Lu is under
intense clinical investigation. There are significant differences in the physical characteristics
of these three nuclides and as a result, the choice of radionuclide is very al in order to
deliver maximum ion dose to a tissue of interest. The higher beta energy particles of
90Y may be good for bulky tumors. The relatively low energy beta les of 131I are ideal,
but in vivo dehalogenation of radioiodinated molecules is a major disadvantage for
internalizing dy. In st, 177Lu has low energy beta particle with only 0.2—0.3 mm
range and delivers much lower radiation dose to bone marrow compared to 90Y. In addition,
due to longer physical half—life (compared to 90Y), the residence times are higher. As a result,
higher activities (more mCi amounts) of 177Lu labeled agents can be administered with
comparatively less ion dose to marrow. There have been several clinical studies
investigating the use of 177Lu labeled antibodies in the treatment of various cancers.
(Mulligan T et al., 1995, Clin. Canc. Res. 1: 1447—1454; Meredith RF, et al., 1996, J. Nucl.
Med. 37:1491—1496; Alvarez RD, et al., 1997, Gynecol. Oncol. 65: 94—101).
Use of the therapeutic methods to treat autoimmunity has a number of benefits. Since
the antibodies specifically recognize FcRn, other tissue is spared and high levels of the agent
are delivered directly to the site where therapy is required. Treatment can be effectively
red with clinical parameters. Alternatively, these parameters can be used to te
when such treatment should be employed.
WO 67039
An FcRn—binding antibody can be administered in combination with one or more of
the existing modalities for treating mune disorders including, but not d to:
intravenous lg therapy, nonsteroidal anti—inflammatory drugs (NSAID), and osteroids;
and anti—inflammatory treatments such as cyclosporins, rapamycins or cins, or their
immunosuppressive analogs, e.g., cyclosporin A, cyclosporin G, FK—506, rapamycin, 40—O—
(2—hydroxy)ethyl—rapamycin etc.; cyclophosphamide; azathioprene; methotrexate; brequinar;
FTY 720; leflunomide; mnizoribine; mycophenolic acid; mycophenolate mofetil; 15—
deoxyspergualine; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to
leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, or CD58 or
their ligands; or other immunomodulatory compounds, e. g., CTLA4lg, or other adhesion
molecule tors, e.g. mAbs or low molecular weight inhibitors including selectin
antagonists and VLA—4 antagonists. These combination ies can be part of an
immunomodulating regimens or a regimen for the treatment or tion of allo— or
xenograft acute or chronic rejection, an inflammatory disorder, or an autoimmune disorders.
Multiple Sclerosis
le sclerosis (MS) is a central s system disease that is characterized by
inflammation and loss of myelin s.
Patients having MS may be identified by criteria ishing a diagnosis of clinically
definite MS as defined by the workshop on the diagnosis of MS (Poser et al., Ann. Neurol.
13:227, 1983). MS may also be diagnosed by evidence of two attacks and oligoclonal bands
of IgG in cerebrospinal fluid or by combination of an attack, clinical evidence of two lesions
and oligoclonal band of IgG in cerebrospinal fluid. The McDonald criteria can also be used
to diagnose MS. McDonald et al.(200l) Recommended diagnostic criteria for multiple
sclerosis: guidelines from the International Panel on the Diagnosis ofMultiple Sclerosis,
Ann Neurol 50:121—127. The McDonald criteria include the use of MRI evidence of CNS
ment over time to be used in diagnosis of MS, in the absence of le clinical
attacks.
Effective treatment of multiple sclerosis may be evaluated in several different ways.
The following parameters can be used to gauge effectiveness of ent. Two exemplary
criteria include: EDSS (extended disability status scale), and appearance of exacerbations on
MRI (magnetic resonance imaging). The EDSS is a means to grade clinical impairment due
2012/040409
to MS (Kurtzke, Neurology 33: 1444, 1983). Eight functional systems are evaluated for the
type and severity of neurologic impairment. Briefly, prior to treatment, patients are evaluated
for impairment in the following systems: pyramidal, cerebella, brainstem, y, bowel and
bladder, visual, cerebral, and other. Follow—ups are conducted at defined intervals. The scale
ranges from 0 (normal) to 10 (death due to MS). A decrease of one full step can indicate an
effective ent ke, Ann. Neurol. 36:573-79, 1994).
Exemplary symptoms associated with multiple sclerosis, which can be treated with
the methods described herein, e: optic neuritis, diplopia, nystagmus, ocular dysmetria,
internuclear ophthalmoplegia, movement and sound phosphenes, nt pupillary defect,
paresis, monoparesis, paraparesis, hemiparesis, quadraparesis, plegia, paraplegia, hemiplegia,
tetraplegia, quadraplegia, spasticity, dysarthria, muscle atrophy, spasms, cramps, hypotonia,
, nus, myokymia, restless leg syndrome, footdrop, ctional reflexes,
paraesthesia, anaesthesia, neuralgia, neuropathic and enic pain, l'hermitte's,
proprioceptive dysfunction, trigeminal neuralgia, ataxia, intention tremor, dysmetria,
vestibular ataxia, vertigo, speech ataxia, dystonia, dochokinesia, frequent micturation,
bladder spasticity, flaccid bladder, detrusor—sphincter dyssynergia, erectile dysfunction,
anorgasmy, frigidity, constipation, fecal urgency, fecal incontinence, depression, cognitive
dysfunction, dementia, mood swings, emotional lability, euphoria, bipolar me, anxiety,
aphasia, dysphasia, fatigue, fs symptom, gastroesophageal reflux, and sleeping
ers.
In addition to or prior to human studies, an animal model can be used to evaluate the
efficacy of using the two agents. An exemplary animal model for multiple sclerosis is the
experimental autoimmune encephalitis (EAE) mouse model, e.g., as described in (Tuohy et
al. (J. Immunol. (1988) 141: 1126-1130), Sobel et al. (J. Immunol. (1984) 132: 2393-2401),
and Traugott (Cell Immunol. (1989) 119: 9). Mice can be administered a first and
second agent described herein prior to EAE induction. Then the mice are evaluated for
characteristic criteria to determine the cy of using the two agents in the model.
Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) include generally chronic, relapsing intestinal
inflammation. IBD refers to two ct disorders, Crohn's disease and ulcerative colitis
(UC). The clinical symptoms of IBD include intermittent rectal bleeding, crampy abdominal
pain, weight loss and diarrhea. A clinical index can also be used to monitor IBD such as the
Clinical Activity Index for Ulcerative Colitis. See also, Walmsley et al. Gut. 1998
Jul;43(l):29—32 and Jowett et al. (2003) Scand J Gastroenterol. 38(2):l64—7l. An FcRn—
binding antibody can be used to ameliorate at least one symptom of IBD or to ameliorate a
clinical index of IBD.
Rheumatoid Arthritis
Rheumatoid arthritis is an autoimmune inflammatory disease that causes pain,
swelling, stiffness, and loss of function in the . Rheumatoid arthritis often presents in a
symmetrical pattern. The disease can affect the wrist joints and the finger joints closest to the
hand. It can also affect other parts of the body besides the joints. In addition, people with
rheumatoid arthritis may have e, occasional fevers, and a general malaise. Positive
factors for sis of rheumatoid arthritis include the “rheumatoid ” blood antibody
and citrulline antibody. An FcRn—binding antibody can be useful in treating, preventing, or
alleviating rheumatoid arthritis or one or more symptoms of rheumatoid arthritis.
Lupus
Systemic lupus erythematosus (SLE) is an autoimmune disorder that leads to
inflammation and damage to various body tissues. SLE can be mediated by ntibodies
directed against its own DNA. Lupus can affect many parts of the body, including the joints,
skin, kidneys, heart, lungs, blood vessels, and brain. Although various symptoms may
t, some of the most common include extreme e, painful or swollen joints
(arthritis), unexplained fever, skin , and kidney problems. Exemplary ms of
lupus include painful or swollen joints, unexplained fever, and extreme fatigue. A
characteristic red skin rash may appear across the nose and cheeks. Rashes may also occur
on the face and ears, upper arms, shoulders, chest, and hands. Other symptoms of lupus
include chest pain, hair loss, anemia, mouth ulcers, and pale or purple fingers and toes from
cold and stress. Some people also experience headaches, dizziness, sion, confusion, or
seizures. Positive factors for SLE diagnosis include circulating anti—nuclear antibodies, anti—
DNA antibodies, and anti—Sm antibodies. An FcRn—binding antibody can be useful in
treating, preventing, or alleviating SLE or one or more ms of SLE. Lupus, as used
herein es cutaneous lupus and lupus nephritits.
Immune Thromocytopenia (ITP)
ITP is a disease of increased peripheral platelet destruction, where ts develop
antibodies that bind to specific platelet membrane proteins. The anti—platelet antibodies
opsonize the platelets, g to destruction by macrophages. Attempts to treat ITP have
lly involved suppressing the immune system, which causes an increase in platelet
levels. An FcRn—binding antibody can be useful in treating, ting, or alleviating ITP, or
one or more symptoms thereof.
Ankylosing Spondylitis
Ankylosing litis is an autoimmune disorder that not only affects the spine, but
may also affect the hips, shoulders, and knees as the tendons and nts around the bones
and joints become inflamed, resulting in pain and stiffness. Ankylosing spondylitis tends to
affect people in late adolescence or early adulthood. An FcRn—binding antibody can be
useful in treating, preventing, or alleviating ankylosing spondylitis, or one or more symptoms
thereof.
Pemphigus
Pemphigus is an autoimmune disorder that affects mucous membranes and the skin.
The disorder is characterized by the generation of ntibodies against desmoglein.
Desmoglein is a protein in the family of cadherins and is involved with the formation of
omes, which join cells to one another. Pemphigus can be classified as one of three
types: pemphigus vulgaris, the most common form of the disorder, wherein auto—antibodies
target desmoglein 3. In pemphigus folicaeus auto—antibodies against desmoglein 1 are
generated. The third type, and least common er is paraneoplastic pemphigus, wherein
autoantibodies target lakins and which is associated with cancers such as lymphoma.
The disorders are commonly diagnosed by a dermatologist by the appearance of the skin and
is conformed by the ion of auto—antibodies against desmoglein. Methods of treatment
include the administration of steroids and/or the administration of a CD20 antibody such as
RituXimab (Rituxan)
Cancer
“Cancer” as used herein refers to an uncontrolled growth of cells which interferes
with the normal functioning of the bodily organs and systems. Cancers which migrate from
their original on and seed vital organs can eventually lead to the death of the subject
through the onal deterioration of the affected organs. Carcinomas are malignant
cancers that arise from epithelial cells and include adenocarcinoma and squamous cell
oma. Sarcomas are cancer of the connective or supportive tissue and include
arcoma, chondrosarcoma and gastrointestinal stromal tumor. Hematopoietic cancers,
such as leukemia, are able to outcompete the normal hematopoietic compartments in a
subject, thereby leading to hematopoietic failure (in the form of anemia, thrombocytopenia
and neutropenia) ultimately g death. A person of ry skill in the art can classify a
cancer as a sarcoma, oma or poietic cancer.
Cancer, as used herein, includes the following types of cancer, breast cancer, biliary
tract cancer; bladder cancer; brain cancer including astomas and medulloblastomas;
cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer;
gastric cancer; hematological neoplasms including acute lymphocytic and myelogenous
leukemia; T—cell acute lymphoblastic ia/lymphoma; hairy cell leukemia; chromic
myelogenous leukemia, multiple myeloma; AIDS—associated leukemias and adult T—cell
leukemia lymphoma; intraepithelial neoplasms including Bowen's disease and Paget's
disease; liver cancer; lung cancer; lymphomas ing n's disease and lymphocytic
lymphomas; neuroblastomas; oral cancer including squamous cell carcinoma; ovarian cancer
including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells;
pancreatic cancer; prostate cancer; rectal cancer; sarcomas including leiomyosarcoma,
rhabdomyosarcoma, rcoma, fibrosarcoma, and osteosarcoma; skin cancer including
melanoma, Kaposi’s sarcoma, basocellular cancer, and squamous cell cancer; testicular
cancer including germinal tumors such as seminoma, non—seminoma (teratomas,
choriocarcinomas), stromal tumors, and germ cell tumors; thyroid cancer ing thyroid
adenocarcinoma and medullar carcinoma; and renal cancer including arcinoma and
Wilms tumor. Other cancers Will be known to one of ordinary skill in the art.
Treatment ofFetuses
FcRn mediates the transport of maternal IgG across epithelial cell rs to fetus.
The antibodies described herein can be used to deliver macromolecular drugs, e.g.
antibiotics, and/or small molecules to fetuses in utero. The fetus may be suffering from a
condition or disorder (e.g. an enteric infection or metabolic disorder) that requires treatment.
The drug or molecule for treating the condition or disorder can be conjugated to a FcRn
binding antibody and administered to a nt woman who has an in utero fetus that is in
need of treatment. The conjugated FcRn—binding antibody binds to FcRn and is thereby
transported to the fetus via the placenta. The fetus receives the drug or molecule treatment.
Immunadsorption
In some ments, the invention provides methods for the removal of an
unwanted therapeutic antibody from an dual. In some embodiments, the unwanted
therapeutic antibody is an IgG antibody. In some embodiments the unwanted therapeutic
antibody is an anti—VLA4 antibody such as Natalizumab (Tysabri, Biogen Idec/ Elan),
efalizumab (Raptiva, Genentech), bevacizumab (Avastin, Genentech) and PC fusion proteins
such as etanercept (Enbrel, Amgen/Wyeth). Natalizumab onal antibody y has
been associated with Progressive Multifocal Leukoencephalopathy (PML). Depletion of the
therapeutic antibody from the bloodstream and/or the rest of the body may alter the
progression of PML.
In some embodiments, the ent methods presented herein may be combined
with methods to remove or partially remove therapeutic antibodies from the bloodstream of a
subject. In some embodiments, the anti—FcRn antibodies ted herein may be combined
with a capture protein that can bind a therapeutic antibody, the combinations resulting in an
increased clearance of the therapeutic antibody from the bloodstream. In some embodiments,
the method of l or partial removal of the therapeutic antibody from the tream of
a subject is plasma exchange (PLEX). In some embodiments, the anti—FcRn antibodies can
be administered to a subject undergoing plasma exchange. In some embodiments, the anti—
FcRn antibodies can be used as an immunoadsorbant for FcRn in the plasma exchange
process.
In plasma exchange (also called apheresis or plasmapheresis) blood is taken from the
body and plasma containing an unwanted agent, such as cholesterol or a therapeutic antibody,
is removed from the blood by a cell separator. Blood can be d from the body in
batches or it can be removed in a continuous flow mode, with the latter allowing for the
reintroduction of the processed blood into the body. The d plasma comprising the
unwanted agent can be discarded and the t can receive donor plasma or saline with
added proteins in return. In some embodiments, le rounds of plasma exchange may be
2012/040409
needed to remove the unwanted agent from the blood or to lower the level of the unwanted
agent in the blood to an acceptable level. In some embodiments the blood is “filtered” and
the ed agent removed, before returning the blood to the patient. Methods of plasma
exchange are known in the art and are described, for example, in US 6,960,178.
Plasma exchange has been shown to reduce therapeutic antibody levels in the blood of
a subject and the restoration of homeostasis (See e.g., Khatri et al; 2009; Neurology 72:402—
409).
An IgG based therapeutic antibody (such as natalizumab) can be d from blood,
plasma or serum by contacting the blood with the capture protein Staphylococcal protein A,
which will bind the Fc region of IgG and remove the IgG antibody from the bloodstream.
Other capture proteins can be used for ent isotype dies. In some embodiments,
the anti—FcRn antibodies can be used as a capture protein in the plasma exchange process,
resulting in the removal of FcRn from the tream, thereby increasing the amount of
“free” therapeutic antibody. The resulting “free” therapeutic antibody will have a shorter
half—life than antibody present prior to treatment and/or can be removed from the blood more
readily with a ent capture protein (such as protein A). In some embodiments, the anti—
FcRn dies are administered to a patient during or before plasma exchange. In some
embodiments, the cRn antibodies can be immobilized and used in a column, resulting
in the binding of FcRn. In some embodiments, the blood of a patient that ns a
therapeutic dy is contacted both with immobilized anti—FcRn antibody and immobilized
protein A.
In some embodiments the anti—FcRn antibodies presented herein can be used in
“rescue” therapy for therapeutic antibodies that have been administered and have shown an
adverse effect. In some embodiments, an anti—FcRn antibody can be used as an alternative
for plasma exchange. The administration of an anti—FcRn can accomplish therapeutic
antibody depletion without the risks associated with plasmapheresis and plasma exchange
such as vascular access, citrate therapy and donor plasma sourcing.
Human leukocyte antigens
Human leukocyte antigens (HLA) present peptides and antigens on the e of the
cell, which are subsequently recognized by T—cells, which in their turn can activate B—cells.
The panel of HLA genes available is unique for each person. Any cell displaying an HLA
that is “non—self” will result in the induction of an immune response. In general, the more
ent the “non—self” HLA from the self HLA, the stronger the immune response. For
instance, in the case of organ transplants, subjects with similar HLA genes are red to
minimize the immune response. Donor—specific HLA antibodies have been found to be
associated with graft e in kidney, heart, lung and liver transplantation.
In some embodiments, the invention provides s for the decreasing the level of
“non—self” HLA antibodies in an individual. Decreasing the level of “non—self” HLA
antibodies can result in the suppression of an immune response, e.g., during organ
transplantation. In some embodiments a person that will be undergoing organ transplation is
administered an cRn antibody. In some embodiments a person that is undergoing organ
transplation is administered an anti—FcRn antibody. In some embodiments a person that has
received an organ transplation is administered an anti—FcRn dy. Assays for measuring
the levels of HLA antibodies are well—known in the art.
stic Uses
Antibodies that bind to FcRn and identified by the method described herein and/or
detailed herein have in vitro and in vivo diagnostic utilities.
In one aspect, the disclosure es a diagnostic method for detecting the presence
of an FcRn, in vitro or in vivo (e.g., in vivo imaging in a subject). The method can include
localizing FcRn to a subcellular location, 6.57., the endosome. The method can include: (i)
contacting a sample with FcRn—binding antibody; and (ii) detecting formation of a x
between the FcRn—binding antibody and the sample. The method can also include contacting
a reference sample (e.g., a control sample) with the antibody, and determining the extent of
formation of the complex between the antibody and the sample relative to the same for the
reference sample. A change, 6.57., a statistically significant change, in the formation of the
complex in the sample or subject relative to the control sample or subject can be indicative of
the presence of FcRn in the .
r ary method includes: (i) administering the FcRn—binding antibody to a
subject; and (iii) detecting formation of a complex between the FcRn—binding antibody and
the subject. The detecting can include determining location or time of formation of the
complex.
The FcRn—binding antibody can be directly or indirectly labeled with a detectable
substance to facilitate detection of the bound or unbound antibody. Suitable detectable
substances include various s, etic groups, fluorescent materials, luminescent
materials and radioactive materials.
Complex formation between the FcRn—binding dy and FcRn can be ed by
measuring or visualizing either the antibody bound to the FcRn or unbound dy.
Conventional detection assays can be used, e.g., an enzyme—linked immunosorbent assays
(ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry. Further to labeling
the FcRn—binding antibody, the ce of FcRn can be assayed in a sample by a
competition immunoassay utilizing standards d with a detectable substance and an
unlabeled FcRn—binding antibody. In one example of this assay, the biological sample, the
d standards, and the FcRn—binding antibody are combined and the amount of labeled
standard bound to the unlabeled antibody is determined. The amount of FcRn in the sample
is inversely proportional to the amount of labeled standard bound to the FcRn—binding
antibody.
Fluorophore and chromophore labeled antibodies can be prepared. Because
antibodies and other proteins absorb light having wavelengths up to about 310 nm, the
fluorescent moieties should be selected to have substantial absorption at wavelengths above
310 nm and preferably above 400 nm. A y of suitable fluorescers and chromophores
are described by Stryer,l968, Science 162:526 and Brand, L. et al.,l972, Annu. Rev.
Biochem. 4l:843 868. The antibodies can be labeled with cent chromophore groups
by conventional procedures such as those disclosed in US. Patent Nos. 475, 4,289,747,
and 4,376,110. One group of fluorescers having a number of the desirable properties
described above is the xanthene dyes, which include the fluoresceins and rhodamines.
Another group of fluorescent compounds are the naphthylamines. Once labeled with a
fluorophore or phore, the antibody can be used to detect the presence or localization
of the FcRn in a sample, e.g., using fluorescent microscopy (such as confocal or
olution microscopy).
Histological Analysis. Immunohistochemistry can be performed using the antibodies
described herein. For example, the antibody can be sized with a label (such as a
purification or epitope tag), or can be detectably labeled, e. g., by conjugating a label or label—
binding group. For example, a or can be attached to the antibody. The antibody is then
contacted to a histological preparation, e. g., a fixed section of tissue that is on a microscope
slide. After an incubation for binding, the preparation is washed to remove unbound
dy. The preparation is then analyzed, e. 57., using microscopy, to identify if the dy
bound to the preparation.
Of course, the antibody can be unlabeled at the time of binding. After binding and
washing, the antibody is labeled in order to render it able.
Protein . The FcRn—binding antibody can also be immobilized on a protein
array. The protein array can be used as a stic tool, e.g., to screen medical samples
(such as isolated cells, blood, sera, biopsies, and the like). Of course, the n array can
also include other ligands, e. g. that bind to FcRn or to other target molecules.
s of producing polypeptide arrays are described, e.g., in De Wildt et al., 2000,
Nat. Biotechnol. -994; Lueking et al., 1999, Anal. Biochem. 3—1 l 1; Ge, 2000,
Nucleic Acids Res. 28, e3, I—VII; MacBeath and Schreiber, 2000, Science 289:1760—1763;
WO 01/40803 and WO 99/51773Al. Polypeptides for the array can be spotted at high speed,
e.g., using commercially available robotic apparati, e. g., from Genetic MicroSystems or
BioRobotics. The array substrate can be, for example, nitrocellulose, plastic, glass, e.g.,
surface—modified glass. The array can also e a porous matrix, e. 57., acrylamide, agarose,
or another polymer.
For example, the array can be an array of antibodies, e.g., as bed in De Wildt,
supra. Cells that produce the antibodies can be grown on a filter in an arrayed format.
Antibody production is induced, and the expressed polypeptides are immobilized to the filter
at the location of the cell. An dy array can be contacted with a labeled target to
determine the extent of binding of the target to each immobilized antibody. Information
about the extent of binding at each address of the array can be stored as a profile, e.g., in a
computer database. The antibody array can be produced in replicates and used to compare
binding profiles, e.g., of a target and a non—target.
FACS (Fluorescence Activated Cell Sorting). The FcRn-binding antibody can be
used to label cells, e. 57., cells in a sample (e. g., a patient sample). The antibody is also
attached (or able) to a fluorescent compound. The cells can then be sorted using
fluorescence activated cell sorter (e. 57., using a sorter available from Becton Dickinson
Immunocytometry Systems, San Jose CA; see also US. Patent Nos. 5,627,037; 5,030,002;
and 5,137,809). As cells pass through the sorter, a laser beam excites the fluorescent
compound while a detector counts cells that pass through and ines whether a
fluorescent compound is attached to the cell by detecting fluorescence. The amount of label
bound to each cell can be quantified and analyzed to terize the sample.
The sorter can also deflect the cell and separate cells bound by the antibody from
those cells not bound by the antibody. The separated cells can be cultured and/or
characterized.
In vivo Imaging. Also ed is a method for detecting the presence of a FcRn—
expressing tissues in vivo. The method includes (i) administering to a subject (e.g., a patient
having an autoimmune disorder) an anti—FcRn antibody, conjugated to a able marker;
(ii) exposing the subject to a means for detecting said detectable marker to the FcRn—
expressing tissues or cells. For e, the subject is imaged, e. g., by NMR or other
tomographic means.
Examples of labels useful for diagnostic imaging include radiolabels such as 131I9
111 123 3
In, 1,99mTc, 32 125 14 188
P, I, H, C, and Rh, fluorescent labels such as fluoresce1n and-
rhodamine, nuclear ic resonance active labels, positron emitting isotopes detectable by
a positron emission tomography (“PET”) scanner, chemiluminescers such as luciferin, and
enzymatic s such as peroxidase or atase. Short range radiation emitters, such
as isotopes detectable by short range detector probes can also be employed. The antibody can
be d with such reagents using known techniques. For example, see Wensel and
Meares, 1983, Radioimmnnoimaging and Radioimmanotlierapy, Elsevier, New York for
techniques relating to the radiolabeling of antibodies and D. Colcher et al., 1986, Meth.
Enzymol. 121: 802 816.
A radiolabeled antibody can also be used for in vitro diagnostic tests. The specific
ty of a isotopically—labeled antibody s upon the half life, the isotopic purity of
the radioactive label, and how the label is incorporated into the antibody.
Procedures for labeling polypeptides with the radioactive isotopes (such as 14C, 3H,
358, 125I, 32P, 131I) are generally known. For example, tritium ng procedures are
described in US. Patent No. 4,302,438. Iodinating, m labeling, and 358 labeling
procedures, e.g., as adapted for murine monoclonal antibodies, are described, e.g., by Goding,
J .W. (Monoclonal antibodies .' principles and practice .' production and application of
monoclonal antibodies in cell biology, biochemistry, and immunology 2nd ed. London ;
Orlando : Academic Press, 1986. pp 124 126) and the references cited therein. Other
procedures for iodinating ptides, such as antibodies, are described by Hunter and
Greenwood, 1962, Nature 144:945, David et al., 1974, Biochemistry 13:1014 1021, and US.
Patent Nos. 3,867,517 and 4,376,110. Radiolabeling elements which are useful in imaging
- 123 131 111
include I, I, In, and 99mTc, for example. Procedures for iod1nat1ng antibodies are- - - - -
described by Greenwood, F. et al., 1963, Biochem. J. 89:114 123; Marchalonis, J., 1969,
Biochem. J. 113:299 305; and Morrison, M. et al., 1971, Immanochemistry 289 297.
Procedures for 99mTc labeling are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.),
Tumor Imaging: The Radioimmnnochemical ion of Cancer, New York: Masson 111
123 (1982) and the references cited therein. Procedures suitable for In ng antibodies
are described by Hnatowich, D]. et al., 1983, J. Immunol. s, 65:147 157, ich,
D. et al., 1984, J. Applied Radiation, 35:554 557, and Buckley, R. G. et al., 1984, F.E.B.S.
166:202 204.
In the case of a radiolabeled antibody, the antibody is administered to the patient, is
localized to cells bearing the antigen with which the antibody reacts, and is detected or
“imaged” in vivo using known ques such as radionuclear scanning using e.g., a gamma
camera or emission tomography. See e. 57., AR. Bradwell et al., “Developments in Antibody
Imaging”, Monoclonal Antibodies for Cancer ion and Therapy, R.W. Baldwin et al.,
, pp 65 85 (Academic Press 1985). Alternatively, a positron emission transaxial
tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory,
can be used where the radiolabel emits ons (e.g., 11C, 18F, 15O, and 13N).
MRI Contrast Agents. Magnetic Resonance Imaging (MRI) uses NMR to visualize
internal features of living subject, and is useful for prognosis, diagnosis, treatment, and
surgery. MRI can be used without radioactive tracer compounds for s benefit. Some
MRI techniques are summarized in EP—A—0 502 814. Generally, the differences related to
tion time constants T1 and T2 of water protons in different environments is used to
te an image. r, these differences can be insufficient to provide sharp high
resolution images.
The differences in these relaxation time constants can be enhanced by contrast agents.
Examples of such contrast agents include a number of magnetic agents paramagnetic agents
(which primarily alter T1) and ferromagnetic or superparamagnetic (which ily alter T2
response). Chelates (e.g., EDTA, DTPA and NTA chelates) can be used to attach (and
reduce ty) of some paramagnetic substances (e.g., . Fe”, Mn”, Gd+3). Other agents can
2012/040409
be in the form of les, e.g., less than 10 mm to about 10 nM in diameter). Particles can
have ferromagnetic, antiferromagnetic, or superparamagnetic properties. Particles can
include, e. g., magnetite (Fe3O4), y—Fe203, ferrites, and other magnetic mineral compounds of
transition elements. Magnetic particles may include: one or more magnetic crystals with and
without nonmagnetic material. The nonmagnetic al can include synthetic or natural
polymers (such as sepharose, dextran, dextrin, starch and the like.
The FcRn—binding antibody can also be d with an indicating group containing of
the NMR active 19F atom, or a plurality of such atoms inasmuch as (i) substantially all of
naturally abundant fluorine atoms are the 19F e and, thus, substantially all fluorine
containing compounds are NMR ; (ii) many chemically active polyfluorinated
compounds such as trifluoracetic anhydride are commercially available at relatively low cost;
and (iii) many fluorinated compounds have been found medically acceptable for use in
humans such as the orinated polyethers utilized to carry oxygen as hemoglobin
replacements. After permitting such time for incubation, a whole body MRI is carried out
using an apparatus such as one of those described by Pykett, 1982, Sci. Am. 246:78 88 to
locate and image tissues expressing FcRn.
The disclosure also features kits comprising an antibody that binds to FcRn and
instructions for diagnostic use, e.g., the use of the FcRn—binding antibody or antigen—binding
fragment thereof, to detect FcRn, in vitro, e.g., in a sample, e.g., a biopsy or cells from a
patient having an autoimmune disorder, or in vivo, e.g., by imaging a subject. The kit can
further contain a least one additional reagent, such as a label or additional diagnostic agent.
For in viva use the antibody can be ated as a pharmaceutical composition.
The present ion is further illustrated by the ing Examples, which in no
way should be construed as further limiting. The entire contents of all of the references
(including literature references, issued patents, published patent applications, and co—pending
patent applications) cited throughout this application are hereby sly incorporated by
reference, in particular for the teaching that is referenced hereinabove.
EXAMPLE 1: DX2504 and Cysteine s Thereof
The light chain of the DX—2504 anti—FcRn antibody has an unpaired cysteine in the
first on of CDR3. This cysteine is adjacent to the cysteine in the FR3 that pairs with the
cysteine in the FRl of light chains. We constructed two mutants that replace the cysteine in
the CDR3 with either a serine or an alanine. (See below and see also Figure 9).
l) 532A—X53—C02: cys to ser mutant
2) 532A—X54—B03: cys to ala mutant
Sequence Alignment of the Light Chains of DX—2504 (SEQ ID NO:8), 532A-X53—C02 (SEQ
ID , and 532A-X54-B03 (SEQ ID NO:ll)
FRl—L CDRl—L FR2—L CDR2—L
DX—2504: QSAJTQPASVSGSPGQSITISC TGTGSDVGSYNAVS WYQQHPGKAPKJMIY GDSQRPS
532A—X53—C02 QSAJTQPASVSGSPGQSITISC TGTGSDVGSYNJVS WYQQHPGKAPKAMIY GDSQRPS
532A—X54—303 QSAJTQPASVSGSPGQSITISC TGTGSDVGSYNJVS WYQQHPGKAPKAMIY GDSQRPS
FR3—L CDR3—L FR4—L
DX—2504: SGSKSGNTAS.TISG.QAfiDfiADYYC ESYAGSGIYV FGTGTKVTVJ
532A—X53—C02: GVSBRFSGSKSGNTAS.TISG.QAfiDfiADYYC ESYAGSGIYV FGTGTKVTVJ
532A—X54—303: GVSBRFSGSKSGNTAS.TISG.QAfiDfiADYYC GIYV VTVJ
Size exclusion chromatography (SEC) analysis 504, 532A-X53-C02 and 4-
303
Antibody purity was assessed by injecting 50 ug protein over a Tosoh G3000 SWXL
column equilibrated in 0.2M Sodium Phosphate, pH: 6.9 on a Waters 2695 HPLC system
with UV detection. Integrated peak areas were expressed as % r (i. e. intact
antibody), % high molecular weight aggregates (%HMW), and % low molecular weight
species (%LMW) in Table I. (See also Figure I).
Table 1. Summary of SEC Results
% HMWA % LMW
SDS-PAGE analysis 0fDX-2504, 532A-X53-C02 and 532-X54-BO3
Antibodies were treated with 50 mM N—ethylmaleimide followed by SDS—PAGE
sample buffer and heated for 10 minutes at 72°C to block free thiol that may lead to gel
artifacts. Antibody (4 ug) was loaded onto a 4—12 % gradient NuPAGE gel and stained with
Simply Blue Safe Stain, prior to densitometry analysis using a UVP system (Table 2). (See
also Figure 2)
Table 2. Summary of Densitometry Analyses
Densitometry Analysis on Non-reduced mAb Samples
Band I.D. DX-2504 532A-X54-B03 532A-X53-C02
2H/2L (Monomer) 81.6% 92.8% 92.4%
2H/1L 13.8% 6.8%
0.9%
Temperature stability 0fDX-2504, 532A-X53-C02 and 532-X54-BO3
DX—2504, 532A—X53—C02 and 532—X54—B03_samples were incubated at 37°C for 1
month. Samples were taken at different time points for analysis using ical SEC.
ature stability of DX—2504 and ne mutants is presented based on the change in
% monomer. (See Figure 3).
pH Stability 0fDX-2504, 532A-X53-C02 and 532-X54-BO3
4, 532A—X53—C02 and 532—X54—B03 samples were incubated in different pH
conditions at room temperature for 1 month. Samples were taken at different time points for
analysis using analytical SEC. pH stability of DX—2504 and cysteine s is presented
based on the change in % monomer. (See Figure 4).
Stability 0fDX-2504, 532A-X53-C02 and 532-X54-BO3 atpH 8.3
Stability was assessed using SEC as bed in the paragraph above Table 1. The
SEC is of the antibodies at pH 8.3 is shown since it illustrates the improved stability of
the cysteine mutants over DX—2504 at tested pH condition. (See Figure 5).
Thiol titration with DTNB
The presence of free cysteine thiols in the purified antibody ons was ed by
reacting 10 uM antibody with 10 mM DTNB (Ellman’s reagent, or ithio—bis (2—
nitrobenzoic acid)) in the presence or absence of the denaturation reagent 6 M guanidine
hydrochloride for 0.5 hours at 37°C before reading the absorbance of the reaction at 412 nm
(8 = 14,100 M'lcm'l). The concentration of thiol was diVided by the concentration of
antibody to obtain the mol thiol/mol of mAb. (See Table 3 below).
Table 3. Summary of Thiol Titration Data
DTNB Assay - 10 uM mAb
Free Thiol/mol mAb Free Thiol/mol mAb
Sample ID
Not Denatured Denatured
DX-2504 0.62
532A-X54-B03 0.05 0.31
532A-X53-C02 0.05 0.25
ity ofDX-2504, 532A-X53-C02 and 532-X54-BO3 towards chemical denaturation.
Protein stability of DX—2504 and ne mutants was ed by ring
intrinsic cence as a on of chemical rant guanidine hydrochloride (GuHCl)
tration. 1mg/ml of each antibody product were prepared with different tration
of GuHCl 1 to 8M. Fluorescence was measured and the intensity ratio of 360/330 as a
function of GuHCl concentration is plotted. Cysteine mutants show better stability for
structural conformation changes against denaturant reagent. (See Figure 6).
Surface plasmon resonance (SPR or Biacore) kinetic analysis ofthe interaction ofhFcRn
with immobilized DX-2504, 532A-X53-C02 and 532-X54-BO3.
SPR measurements were performed using a Biacore 3000. DX—2504, 532A—X53—C02
and 4—B03 were immobilized by amine coupling on CM5 sensor chips at
immobilization densities of ~220 RU. To measure the kinetic parameters of DX—2504
interaction with FcRn analyte, twofold serial dilutions prepared from 100 nM of FcRn were
injected in duplicate for 5 min at 50 l/min with a 15 minute dissociation phase. The sensor
chip surface was regenerated with a 30 sec pulse of 10 mM glycine pH 1.5 at a flow rate of
75 l/min followed by a 15 second pulse of buffer. Measurements were performed at 25°C
using HBS—P as the running buffer. The reference flow cell was activated and blocked in a
mock amine coupling reaction. The data was fit to a 1:1 binding model using Biaevalution
V.4.1 software. (See Table 4, Figure 7 and Figure 8).
2012/040409
Table 4. Summary of SPR Results
pH 6-0
532A—X54—B03 1.1 x 10 2.2 x 10'
pH 7.5 53—C02 1.9 x 10 3.2 x 10‘
DX-2504 lot 040709 1.5 x 10 2.8 x 10'
EXAMPLE 2: on Mutant of DX—2504
The heavy chain of the DX—2504 anti—FcRn antibody contains a lysine at the last
position (C—terminus) in the heavy chain. Mutant DX—2507 (light chain SEQ ID NO: 18,
heavy chain SEQ ID NO:19) contains the same light chain as that of DX—2504 and a mutated
heavy chain, which was constructed by deleting the C—terminal lysine residue in the heavy
chain of DX—2504. A sequence alignment n the C—terminal fragment of DX—2504
heavy chain (SEQ ID NO:20) and that of DX—2507 heavy chain (SEQ ID NO:21) is shown
below:
DX—2504: SDGSFF .YSK .TVDKSRWQQGNVFSCSVMH'QA .HNHYTQKS .S -SPGK
DX—2507: SDGSFF .YSK .TVDKSRWQQGNVFSCSVMH'QA .HNHYTQKS -S -SPG
Pharmacologic profile and Toxicokinetic profile ofDX-2504 and DX-2507 in Cynomolgus
Monkeys
SiX naive female cynomolgus monkeys were assigned to 2 dose groups each
consisting of 3 animals. Table 5 provides a summary of the study design. All animals were
dosed 20mg/kg of the test antibody via subcutaneous (SC) injection once on Study Day 0 and
Study Day 7. Group 1 animals were administered DX—2504 and Group 2 animals were
administered 7. Blood was collected from all animals at the ing time points:
Day 0 (prior to dosing and 2 and 12 hours post—dose), Days 1, 2, ,3 ,4 ,5 ,6, Day 7 (prior to
dosing and 2 and 12 hours ose), Days 8, 9, 10, 11, 12, 13, 14, 17, 21, 24, 28, 31 and 35.
Serum samples for toxicokinetics of DX—2504 and DX—2507 were analyzed using a qualified
ELISA method (DRD—910—029). Total cynomolgus monkey IgG levels were analyzed using
a qualified ELISA method (DRD_910—033).
Table 5: Study Design
Group # of Test Ab Dose level Route Dose Dose
Animals (mg/kg/dose) Concentration volume
(m_ mL) (mL/k_)
DX—2504 serum concentrations were detected from 2 hours post—dose on Day 0
through Day 11 in 2 animals and Day 13 in one animal. DX—2507 serum concentrations were
ed from 2 hours post—dose on Day 0 through Day 11, Day 12, and Day 17 in individual
animals. The results thus obtained show that the serum concentrations of DX—2507 were
much higher than those of DX—2504 in the test animals, indicating that DX—2507 was more
stable in Vivo than DX—2504. Figure 13.
Cynomolgus monkey IgG levels were reduced following administration of both DX—
2504 and DX—2507 (Figure 14). Following administration of the Day 0 dose, mean total IgG
levels were reduced to 42% and 33% of pre—dose baseline levelsin the DX—2504 and DX—
2507 dose groups, respectively. Prior to the Day 7 dose, mean total IgG levels increased to
45% and 37% of predose baseline levels in the same treatment groups. Following
stration of the Day 7 dose, mean total IgG levels were reduced to 42% of predose
baseline values in the DX—2504 group and to 30% of predose baseline values in the 7
group. Total IgG levels d to predose baseline values on Day 13 in the DX—2504—treated
animals and on Day 21 in the DX—2507—treated animals.
The mean toxicokinetic parameters for DX—2504 and 7 are summarized in
Table 6.
Table 6: Mean (SD) Toxicokinetic parameters
Cmax t CL/F VZ/F 11/2 (d)
(ug/mL) (d*ug/mL) (mL/d/Kg) )
—-70.8 341.0 879.1 1.9
(25.8) (32.2) (204.5) (407.0) (0.2)
DX_2504
47.5 492.3 312.4 0.4
(15.7) (20.0) (264.0) (252.0) (0.1)
n-135.6 152.0 74.1 0.3
(19.7) (29.4) (31.8) (35.0) (0.1)
DX'2507
120.3 166.3 73.6 0.3
(4.7) (3.2) (4.3) (24.8) (0.1)
>"Serum concentration es were corrected for e (Day 7) baseline concentrations
The toxicokinetic parameters for both DX-2504 and DX-2507 were
substantially consistent on days 0 and 7. The overall exposure of DX-2507 was
greater than that observed for DX-2504. The mean maximum concentration (Cmax)
and plasma/serum concentration-time curve (AUCiast) values for DX-2507 on either
Day 0 or Day 7 were between 2 to 3-fold greater than the corresponding values
calculated for DX-2504. In addition, the corresponding mean apparent clearance
(CL/F) and distribution volume (Vz/F) values for DX-2504 were between 2 to 12-fold
greater than DX-2507.
Equivalents
The foregoing written specification is considered to be sufficient to enable one
skilled in the art to practice the invention. The present invention is not to be limited in
scope by examples provided, since the examples are intended as a single illustration
of one aspect of the invention and other functionally equivalent embodiments are
within the scope of the invention. s modifications of the invention in addition
to those shown and described herein will become apparent to those d in the art
from the foregoing ption and fall within the scope of the appended claims. The
advantages and objects of the invention are not necessarily encompassed by each
ment of the ion.
The contents of all nces, s and published patent applications cited
throughout this ation are incorporated herein by reference in their entirety,
particularly for the use or subject matter referenced .
Throughout the specification and claims, unless the context requires otherwise,
the word “comprise” or variations such as “comprises” or “comprising”, will be
understood to imply the inclusion of a stated integer or group of rs but not the
exclusion of any other integer or group of integers.
Claims (18)
1. An isolated antibody comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the antibody binds to human FcRn; and wherein the VL comprises: 5 (i) a VL CDRl comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14), (ii) a VL CDR2 comprising the amino acid sequence S (SEQ ID NO: 15), and (iii)a VL CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ 10 ID NO: 12) or ASYAGSIYV (SEQ ID NO: 13), and the VH comprises: (i) a VH CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22); (ii) a VH CDR2 sing the amino acid sequence 15 SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) a VH CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24).
2. The isolated antibody of claim 1, wherein the VL of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11. 20
3. The isolated antibody of claim 1, wherein the VH of the isolated antibody comprises the amino acid ce of SEQ ID NO:9.
4. An ed antibody comprising a light chain variable region (VL), a heavy chain that comprises a heavy chain le region (VH) and a heavy chain constant region, wherein the antibody binds to human FcRn; and wherein the VL 25 comprises: (i) a VL CDRl comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14), (ii) a VL CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15), and (iii)a VL CDR3 sing the amino acid sequence CSYAGSGIYV (SEQ ID NO: 25), SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSIYV 5 (SEQ ID NO: 13), and the VH comprises: (i) a VH CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22) (ii) a VH CDR2 comprising the amino acid sequence comprising 10 the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and (iii) VH CDR3 sing the amino acid sequence LAIGDSY (SEQ ID NO: 24); and the CH has a deletion corresponding to the C-terminal lysine e at the 15 last position of SEQ ID NO: 17.
5. The isolated antibody of claim 4, wherein the VL of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 11.
6. The antibody of any one of claims 1-4, wherein the antibody binds 20 human FcRn with a dissociation constant (KD) of less than 10 nM.
7. The dy of any one of claims 1-4, wherein the antibody is a human or humanized antibody or is non-immunogenic in a human.
8. The antibody of any one of claims 1-4, wherein the antibody is chimeric. 25
9. The antibody of any one of claims 1-4, wherein the antibody is ed from the group consisting of Fab, F(ab)'2, Fv, and scFv.
10. A pharmaceutical ition comprising the dy of any one of claims 1-4 and a pharmaceutically acceptable carrier.
11. An isolated nucleic acid comprising a nucleotide sequence that encodes the dy of any one of claims 1-4. 5
12. A vector comprising the nucleic acid of claim 11.
13. A host cell comprising the vector of claim 12, wherein the host cell is cultured in vitro.
14. An in vitro method of detecting an FcRn in a , the method comprising: 10 ting the sample with the antibody of any one of claims 1-4, and detecting an interaction between the antibody and the FcRn if present.
15. The antibody of any one of claims 1-4, for use in detecting an FcRn in a subject.
16. Use of the antibody of any one of claims 1-4 in manufacturing a 15 medicament for modulating an FcRn activity.
17. Use of the antibody of any one of claims 1-4 in manufacturing a medicament for treating an autoimmune disorder in a subject.
18. Use of the antibody of any one of claims 1-4 in the manufacture of a medicament for modulating the half life/levels of circulating IgG in a subject.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ715057A NZ715057B2 (en) | 2011-06-02 | 2012-06-01 | Fc Receptor Binding Proteins |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492617P | 2011-06-02 | 2011-06-02 | |
US61/492,617 | 2011-06-02 | ||
US201161498266P | 2011-06-17 | 2011-06-17 | |
US61/498,266 | 2011-06-17 | ||
PCT/US2012/040409 WO2012167039A1 (en) | 2011-06-02 | 2012-06-01 | Fc RECEPTOR BINDING PROTEINS |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ618046A NZ618046A (en) | 2016-02-26 |
NZ618046B2 true NZ618046B2 (en) | 2016-05-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11739152B2 (en) | Antibodies which bind Fc receptors (FcRn) | |
EP2310415B1 (en) | Antibodies against fcrn and use thereof | |
AU2012262007A1 (en) | Fc receptor binding proteins | |
NZ618046B2 (en) | Fc RECEPTOR BINDING PROTEINS | |
AU2015200004A1 (en) | Antibodies against fcrn and use thereof | |
NZ715057B2 (en) | Fc Receptor Binding Proteins |